documents incorporated reference portions proxy statement filed april part iii part item business description bristolmyers squibb company general bristolmyers squibb company bristolmyers squibb company incorporated laws state delaware august name bristolmyers company successor new york business started bristolmyers company changed name bristolmyers squibb company result merger company divisions subsidiaries major producer distributor pharmaceuticals healthcare related products three reportable segmentspharmaceuticals nutritionals healthcare company announced planned divestiture clairol zimmer businesses accordingly operations businesses beenreflected discontinued operations accompanying consolidated financial statements november company completed sale clairol billion august company spun zimmer holdings inc taxfree distribution october company acquired dupont pharmaceuticals business dupont ei du pont de nemours company billion cash dupont primarily domestic pharmaceutical imaging product business focused research development addition november company purchased million shares imclone systems incorporated imclone per share million represented shares outstanding prior company 's commencement public tender offer imclone shares equity investment imclone part strategic agreement company imclone also includes arrangement codevelop copromote investigational cancer drug erbitux transactions financed proceeds issuance billion commercial paper issuance billion mediumterm notes internal cash flows company 's internet website address wwwbmscom company makes available free charge website annual quarterly current reports including amendments reports soon reasonably practicable company electronically files material furnishes material securities exchange commission business segments reference made note segment information consolidated financial statements company three reportable segmentspharmaceuticals nutritionals healthcare pharmaceuticals segment pharmaceuticals segment manufactures distributes sells branded generic ethical pharmaceuticals products sold worldwide primarily wholesalers retail pharmacies hospitals medical profession company manufactures products us puerto rico fifteen foreign countries pharmaceuticals sales accounted approximately company 's sales company 's sales respectively sales selected products product categories pharmaceuticals segment follows pharmaceuticals dollars millions pravachol oncology therapeutics network plavix taxol paraplatin avapro sustiva zerit monopril coumadin glucophage xr videxvidex ec glucovance serzone glucophage ir buspar pravachol pravastatin sodium hmg coa reductase inhibitor indicated primary hypercholesterolemia composition matter patent scheduled expire us october extended six months pediatric extension law april patents expire expired internationally oncology specialty distributor anticancer medicines related products company entered agreement therapeutics mckesson corporation distribution pharmaceutical products relating otn company accounts sales network otn agreement using consignment model described fully item management 's discussion analysis financial condition results operations part ii plavix clopidogrel platelet inhibitor codeveloped jointly marketed sanofisynthelabo composition matter patents us expire july november internationally discussion related litigation reference made item legal proceedings part note litigation matters consolidated financial statements taxol paclitaxel used treatment refractory ovarian cancer firstline treatment ovarian cancer combination cisplatin secondline treatment aids related kaposi 's sarcoma treatment metastatic breast cancer failure combination chemotherapy adjuvant treatment node positive breast cancer treatment nonsmall cell lung carcinoma cisplatin data exclusivity taxol japan expire july european union september patents covering various aspects taxol extend beyond japan europe discussion related litigation reference made item legal proceedings part note litigation matters consolidated financial statements paraplatin carboplatin chemotherapeutic agent used treatment ovarian cancer patent expired france june expire us april avapro irbesartan angiotensin ii receptor antagonist indicated treatment hypertension codeveloped jointly marketed sanofisynthelabo composition matter patent us expires september internationally sustiva antiretroviral drug used treatment hiv sustiva acquired part dupont acquisition completed october composition matter patent expires method use patent expires zerit stavudine used treatment persons advanced human immunodeficiency virus hiv disease patent scheduled expire us june extended six months pediatric extension law december patent expires internationally monopril fosinopril sodium secondgeneration angiotensin converting enzyme ace inhibitor onceaday dosing indicated treatment hypertension composition matter patent us expired december extended six months pediatric extension law expected expire june composition matter patents expire expired internationally coumadin oral anticoagulant used predominantly patients atrial fibrillation dvtpulmonary embolism coumadin acquired part dupont acquisition completed october glucophage ir metformin oral antidiabetes agent type noninsulindependent diabetes hatchwaxman exclusivity expired glucophage xr glucophage ir september however generic metformin become available us january glucovance hatchwaxman data protection expire glucophage xr october glucovance july videxvidex ec didanosine antiretroviral drug used treatment adult pediatric patients advanced hiv infection method use patent expires us august internationally patent held national institutes health company 's license patent became nonexclusive october hatch waxman data protection videx ec expires may serzone nefazodone antidepressant treatment patent expired us march extended six months pediatric extension law expected expire september patents expire expired internationally buspar buspirone antianxiety agent persistent anxiety without accompanying depressive symptoms us anxiolytic use patent expired may us food drug administration fda granted company additional six months exclusivity based performance pediatric studies patents outside us expired discussion related litigation reference made item legal proceedings part note litigation matters consolidated financial statements nutritionals segment nutritionals segment manufactures distributes sells infant formulas nutritional products products generally sold wholesalers retailers promoted primarily consumers worldwide advertising company manufactures products us puerto rico five foreign countries nutritionals sales accounted company 's sales sales selected products product categories nutritionals segment follows dollars millions enfamil enfalac nutramigen prosobee children 's nutritional supplements healthcare segment healthcare segment consists convatec medical imaging consumer medicines us japan healthcare sales accounted company 's sales company 's sales convatecconvatec manufactures distributes sells ostomy modern wound skin care products principal brands convatec include surfit esteem aquacel duoderm products marketed sold worldwide primarily hospitals medical profession company manufactures products us united kingdom convatec sales accounted approximately company 's sales medical imaging medical imaging manufactures distributes sells cardiovascular imaging products principal brands medical imaging include cardiolite definity products marketed sold worldwide primarily hospitals medical profession company manufactures products us puerto rico medical imaging purchased part dupont acquisition completed october sales accounted company 's sales respectively consumer medicines consumer medicines manufactures distributes sells overthecounter health care products principal consumer health care brands include excedrin bufferin comtrex products generally sold retailers promoted primarily consumers us japan advertising products manufactured us puerto rico japan consumer medicines sales accounted company 's sales company 's sales sources availability raw materials general bristolmyers squibb purchases principal raw materials supplies open market substantially materials obtainable number sources loss one source supply would material adverse effect company patents trademarks licenses company owns licensed number patents us foreign countries covering products also developed many brand names trademarks products company considers overall protection patent trademark license rights material value acts protect rights infringement us patents expected expire next three years include patent cefzil december one several patents relating plavix july addition use patent paraplatin expire april hatchwaxman data protection expire glucophage xr october glucovance july expiry dates could extended six months pediatric extension upon completion acceptance pediatric studies fda advance expiration company received six month pediatric extension composition matter patent monopril expected expire june composition matter patent serzone expected expire september patent covering formulation videx ec expected expire may except respect plavix discussed item legal proceedings part note litigation matters consolidated financial statements company believes single patent license material importance relation business whole competition distribution customers markets bristolmyers squibb competes generally broadbased highly competitive principal means competition used market products bristolmyers squibb include quality service price product performance pharmaceutical products products convatec promoted national international basis medical journals directly medical profession company also using directtoconsumer advertising number pharmaceutical products products bristolmyers squibb generally advertised promoted national international basis use television radio print media consumer offers window instore displays bristol myers squibb 's products principally sold wholesale retail trade nationally internationally certain products also sold drug manufacturers hospitals medical profession sales amerisourcebergen corporation cardinal health inc cardinal mckesson corporation mckesson accounted approximately company 's net sales sales cardinal mckesson accounted approximately respectively company 's net sales company accounts certain sales pharmaceutical products cardinal mckesson using consignment model discussion company 's accounting using consignment model relationship wholesalers see note accounting policies consolidated financial statements item management 's discussion analysis financial condition results operations part ii research development research development essential bristolmyers squibb 's business pharmaceutical research development carried bristolmyers squibb pharmaceutical research institute major facilities princeton hopewell new brunswick new jersey wallingford connecticut pharmaceutical research development also carried various facilities us belgium canada france united kingdom management continues emphasize leadership innovation productivity strategies success pharmaceutical research institute bristolmyers squibb spent million million million company sponsored research development activities pharmaceutical research development spending percentage pharmaceutical sales compared regulation aspects company 's business subject degree government regulation countries operations conducted company 's policy comply fully regulatory requirements applying products operations products countries governmentregulation significant general trend towards stringent regulation company devotes significant time effort expense addressing extensive governmental regulatory requirements applicable business governmental regulatory actions result recall seizure products suspension revocation authority necessary production sale product civil criminal sanctions us drug medical device diagnostic food industries company operates long subject regulation various federal state local agencies primarily product manufacture safety efficacy advertising labeling addition governmental bodies us well countries expressed concern costs relating health care cases focused attention pricing drugs appropriate drug utilization government regulation areas already exists countries may expanded significantly us countries future company unable predict extent business may affected future regulatory developments believes substantial experience dealing governmental regulatory requirements restrictions operations throughout world development new improved products enable compete effectively within environment employees bristolmyers squibb employed approximately people december domestic foreign operations reference made note financial instruments note segment information consolidated financial statements international operations subject certain risks inherent conducting business abroad including possible nationalization expropriation price exchange controls limitations foreign participation local enterprises restrictive governmental actions addition changes relative value currencies take place time time effects may favorable unfavorable bristolmyers squibb 's operations currency restrictions relating repatriation earnings certain countries item properties bristolmyers squibb 's world headquarters located park avenue new york new york leases approximately square feet floor space approximately square feet sublet others bristolmyers squibb manufactures products major worldwide locations aggregate floor space approximately square feet facilities owned bristolmyers squibb following table illustrates geographic location company 's significant manufacturing facilities united states europe mideast africa western hemisphere pacific total portions facilities facilities owned leased bristolmyers squibb us elsewhere used research administration storage distribution bristolmyers squibb 's facilities well maintained adequately insured satisfactory condition item legal proceedings various lawsuits claims proceedings pending company certain subsidiaries significant described taxol litigation company filed several lawsuits asserting number generic drug companies infringed patents covering methods administering paclitaxel filed abbreviated new drug applications seeking regulatory approval sell paclitaxel actions consolidated discovery us district court district new jersey district court company assert monetary claim defendants sought prevent defendants marketing paclitaxel manner violates patents defendants asserted infringe company 's patents patents invalid unenforceable early district court invalidated claims company 's patents issue april us court appeals federal circuit affirmed district court 's summary judgment invalidity two claims patents issue two claims relate lowdose threehour administration paclitaxel patient given specified regimen premedicants administration paclitaxel appellate court remanded two claims district court proceedings company filed additional patent infringement suit another company seeking market generic paclitaxel september one defendants received final approval us food drug administration fda abbreviated new drug application paclitaxel marketing product fda since announced additional final approvals sales additional generic products begun defendants asserted counterclaims seeking damages alleged antitrust unfair competition violations company believed patents valid filed suits counterclaims asserted believed without merit lawsuits defendants asserted counterclaims settled defendants agreeing drop claims relating paclitaxel company granting licenses certain paclitaxel patent rights since filing initial patent infringement suits six private actions filed parties alleging antitrust consumer protection similar claims relating company 's actions obtain enforce patent rights plaintiffs seek declaratory judgment damages including treble andor punitive damages allowed disgorgement injunctive relief june group state attorneys general district columbia puerto rico virgin islands brought similar claims september federal trade commission ftc initiated investigation relating paclitaxel january company announced reached agreements principle would settle substantially antitrust litigation surrounding taxol amount taxol antitrust settlements expected million full amount accrued third quarter certain important terms conditions settlements remain finalized certain settlements require court approval final approval state attorneys general taxol litigation contingent upon agreements relating terms injunctive relief among provisions remaining negotiated terms incorporating certain claimants including number health insurers existing settlement framework company discussions number insurers whether ultimately join proposed settlement predicted certainty time company also reached agreement ftc staff terms consent order would resolve ftc 's investigation proposed consent order subject review approval ftc commissioners respect abovementioned proposed settlements possible time reasonably assess final outcome lawsuits reasonably estimate possible loss range loss respect lawsuits proposed settlements become final resolve taxolrelated antitrust consumer protection similar claims company prevail final nonappealable determinations ensuing litigation impact could material buspar litigation november company obtained patent us patent ' patent relating method using buspar buspirone company timely submitted information relating ' patent fda listing fda publication commonly known orange book fda thereafter listed patent orange book delisting patent suits genericdrug manufacturers sued fda company compel delisting ' patent orange book although one district court declined order delisting ' patent another ordered company cause delisting patent orange book company complied court 's order appealed decision united states court appeals federal circuit appellate court reversed district court ordered delisting concurrently company sought enforce ' patent actions two generic drug manufacturers antitrust suits following delisting ' patent orange book number purchasers buspirone several generic drug makers filed lawsuits company alleging improperly triggered statutory marketing exclusivity plaintiffs claimed violation antitrust consumer protection similar laws attorneys general states puerto rico also filed suit company parallel allegations plaintiffs amended allegations include charges agreement company generic company improperly blocked entry generic buspirone market plaintiffs seek declaratory judgment damages including treble andor punitive damages allowed disgorgement injunctive relief multidistrict litigation mdl proceedings judicial panel mdl granted company 's motions patent antitrust cases consolidated single forum court buspirone litigations pending issued two opinions dated february first opinion court found ' patent cover uses buspirone therefore infringed second opinion court denied company 's motion dismiss federal antitrust various state law claims second opinion allows claims company proceed except federal antitrust claims damages accrued four years filing complaints government investigations ftc number state attorneys general initiated investigations concerning matters alleged antitrust suits discussed company cooperated investigations number attorneys general filed action company noted proposed settlements january company announced reached agreements principle would settle substantially antitrust litigation surrounding buspar amount buspar settlements expected million million accrued fourth quarter million accrued first quarter million accrued third quarter written settlement agreements number parties signed certain settlements require court approval number health insurers agreed proposed settlement framework whether cases ultimately settled predicted certainty time company also reached agreement ftc staff terms consent order would resolve ftc 's investigation proposed consent order subject review approval ftc commissioners respect abovementioned proposed settlements buspar antitrust litigation possible time reasonably assess final outcome lawsuits reasonably estimate possible loss range loss respect lawsuits proposed settlements become final resolve busparrelated antitrust consumer protection similar claims company prevail final nonappealable determinations ensuing litigation impact could material vanlev litigation april may june company former chairman board chief executive officer charles heimbold jr former chief scientific officer peter ringrose phd named defendants number class action lawsuits alleging violations federal securities laws regulations actions consolidated one action us district court district new jersey plaintiff claims defendants disseminated materially false misleading statements andor failed disclose material information concerning safety efficacy commercial viability product vanlev period november april may plaintiff submitted amended complaint adding allegations company present chairman board chief executive officer peter r dolan former chairman board chief executive officer charles heimbold jr former chief scientific officer peter ringrose phddisseminated materially false misleading statements andor failed disclose material information concerning safety efficacy commercial viability vanlev period april march number related class actions making essentially allegations also filed us district court southern district new york actions transferred us district court district new jersey plaintiff purports seek compensatory damages costs expenses behalf shareholders possible time reasonably assess final outcome litigation reasonably estimate possible loss range loss respect litigation company prevail final nonappealable determinations litigation impact could material plavix litigation company part owner entity plaintiff two pending patent infringement lawsuits united states district court southern district new york entitled sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceuticals holding partnership v apotex inc apotex corp cv rws sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceuticals holding partnership v dr reddy 's laboratories ltd dr reddy 's laboratories inc cv rws suits based us patent discloses claims among things hydrogen sulfate salt clopidogrel marketed plavix us patent discloses claims among things use clopidogrel prevent secondary ischemic event plaintiffs ' infringement position based defendants ' filing abbreviated new drug applications fda seeking approval sell generic clopidogrel prior expiration patents suit possible time reasonably assess final outcome lawsuits reasonably estimate possible loss range loss respect lawsuits patent protection plavix lost impact company 's operations could material securities matters period march may company number current former officers named defendants number securities class action lawsuits alleging violations federal securities laws regulations plaintiffs variously alleged defendants disseminated materially false misleading statements failed disclose material information concerning three different matters safety efficacy commercial viability vanlev discussed company 's sales incentives certain wholesalers inventory levels wholesalers company 's investment relations imclone systems incorporated imclone imclone 's product erbitux discussed allegations concerning vanlev transferred us district court district new jersey consolidated action pending remaining actions consolidated pending us district court southern district new york allegations remaining actions cover period january april plaintiffs seek compensatory damages costs expenses october number company 's officers directors former directors named defendants shareholder derivative suit pending us district court southern district new york company nominal defendant suit alleges among things violations federal securities laws breaches contract fiduciary duty connection company 's sales incentives certain wholesalers inventory levels wholesalers investment imclone imclone 's product erbitux two similar actions pending new york state court plaintiffs seek damages costs attorneys ' fees april sec initiated inquiry wholesaler inventory issues referenced became formal investigation august december investigation expanded include certain accounting issues including issues related establishment reserves accounting certain asset sales october united states attorney 's office district new jersey announced investigation wholesaler inventory issues referenced since expanded cover subject matter sec investigation opinion management material adjustments necessary correct previously issued financial statements recorded part restatement company expect restatement described however company reasonably assess final outcome investigations time company cooperating investigations company 's investigation also continuing possible time reasonably assess final outcome litigations investigations reasonably estimate possible loss range loss respect litigations investigations company producing documents actively cooperating investigations investigations could result assertion criminal andor civil claims company prevail final nonappealable determinations litigations investigations impact could material erisa litigation december first quarter company others named defendants number class actions brought federal employee retirement income security act erisa cases pending us district courts southern district new york district new jersey plaintiffs allege defendants breached various fiduciary duties imposed erisa owed participants bristolmyers squibb company savings investment program program including duty disseminate material information concerning safety data company 's product vanlev company 's sales incentives certain wholesalers inventory levels wholesalers company 's investment relations imclone imclone 's product erbitux connection allegations plaintiffs assert defendants breached fiduciary duties diversify program assets monitor investment alternatives avoid conflicts interest remedy alleged fiduciary breaches cofiduciaries case pending district new jersey plaintiffs additionally allege violation defendants duty disseminate material information concerning alleged anticompetitive activities related company 's products buspar taxol pravachol plaintiffs seek recover losses caused defendants ' alleged violations erisa attorneys ' fees possible time reasonably assess final outcome matters reasonably estimate possible loss range loss respect lawsuits company prevail final nonappealable determinations matters impact could material average wholesale pricing litigation company together number pharmaceutical manufacturers defendant series state federal actions private plaintiffs brought purported class actions complaints filed attorneys general two states one county alleging manufacturers ' reporting prices certain products resulted false overstated average wholesale price awp turn improperly inflated reimbursement paid medicare beneficiariesinsurers state medicaid programs medical plans others health care providers prescribed administered products federal cases many state cases including attorney general cases removed federal courts consolidated pretrial purposes transferred united states district court district massachusetts pharmaceutical industry average wholesale price litigation awp multidistrict litigation september several private plaintiffs awp multidistrict litigation filed master consolidated complaint master complaint superseded complaints preconsolidated constituent cases master complaint asserts claims federal rico statute state consumer protection fair trade statutes company defendants moved dismiss master complaint motions heard january nevada montana attorneys general moved respective cases remanded state court argument motion held march company also defendant related state court proceedings new york new jersey california arizona tennessee one federal court proceeding new york commenced county suffolk new york new jersey state court proceedings currently stayed company defendants removed intend remove state court cases federal court seek transferred awp multidistrict litigation company anticipates county suffolk case also transferred plaintiffs seek damages well injunctive relief aimed manufacturer price reporting practices cases preliminary stage company unable assess outcome possible effect business profitability reasonably estimate possible loss range loss respect cases company together number pharmaceutical manufacturers also received subpoenas document requests various government agencies seeking records relating pricing marketing practices drugs covered medicare andor medicaid requests records come united states attorney 's office district massachusetts office inspector general department health human services conjunction civil division department justice several states company producing documents actively cooperating investigations could result assertion criminal andor civil claims company unable assess outcome reasonably estimate possible loss range loss respect investigations could include imposition fines penalties administrative remedies breast implant litigation company together subsidiary medical engineering corporation mec certain companies remains defendant number claims lawsuits alleging damages personal injuries various types resulting polyurethanecovered breast implants smoothwalled breast implants formerly manufactured mec related company vast majority claims company direct lawsuits resolved settlements trial likewise claims potential claims company registered nationwide class action settlement approved federal district court birmingham alabama revised settlement resolved revised settlement company established accruals respect breast implant product liability litigation company believes possible loss addition amounts accrued material item submission matters vote security holders matters submitted vote security holders fourth quarter year ended december part ia executive officers registrant listed information executive officers company march executive officers elected board directors initial term continues first board meeting following next annual meeting stockholders thereafter elected oneyear term successors elected executive officers serve pleasure board directors name current position age employment history past years peter r dolan senior vice president strategy organizational effectiveness chairman board chief executive officer member corporate staff company president director executive committee company present chairman board chief executive officer company lamberto andreotti vice president general manager italy oncology europe senior vice president president international member worldwide pharma europe division company senior executive committee vice president general manager italy ceei european oncology worldwide medicines pharmaceuticals group international division company president europe worldwide medicines group division company present senior vice president president international harrison bains jr vice president treasurer corporate staff company vice president tax treasury corporate staff vice president acting chief financial officer corporate staff company present vice president tax treasury corporate staff company stephen e bear vice president strategic business development worldwide senior vice president human resources corporate staff beauty carenutritionals medical devices corporate staff company member executive committee vice president marketing business development new york botanical gardens nonprofit organization present senior vice president human resources corporate staff companyandrew g bodnar md vice president strategic business development worldwide senior vice president strategy medical external medicines group division company vice president affairs corporate staff member executive committe corporate development worldwide medicines group division company vice president medical external affairs corporate staff company senior vice president medical external affairs corporate staff company present senior vice president strategy medical external affairs corporate staff company andrew r j bonfield deputy finance director smithkline beecham plc senior vice president chief financial officer corporate chief financial officer smithkline beecham plc executive staff member executive committee director finance bg group plc present senior vice president chief financial officer corporate staff company wendy l dixon phd vice president marketing merck co senior vice chief marketing officer president global marketing president merck co present chief marketing officer president member executive committee global marketing worldwide medicines pharmaceuticals group division company donald j hayden jr senior vice president corporate staff company executive vice president president americas member president worldwide medicines group division company executive committee executive vice president ebusiness strategy corporate staff company executive vice president ebusiness strategy investor relations corporate intelligence corporate staff company executive vice president health care group president north america medicines present executive vice president president americas tamar howson senior vice president director business development senior vice president corporate development corporate smithkline beecham plc biotechnology consultant chief staff member executive committee executive officers business executives present senior vice president corporate development corporate staff company sandra leung associate counsel corporate staff company vice president corporate secretary corporate staff counsel corporate staff company corporate secretary corporate staff company present vice president corporate secretary corporate staff company john l mcgoldrick general counsel senior vice president corporate staff executive vice president general counsel corporate staff company president medical devices group division company member executive committee executive vice president general counsel corporate staff company president medical devices group division company present executive vice president general counsel corporate staff company dean j mitchell vice president general manager specialty divisions strategic president us primary care worldwide medicines group planning business development glaxo wellcome plc senior member executive committee vice president clinical development product strategy glaxosmithkline plc president international worldwide medicines pharmaceuticals group division company present president us primary care worldwide medicines pharmaceuticals group division company james b palmer md frcp senior vice president director group medical regulatory chief scientific officer corporate staff president product strategy glaxo welcome research development pharmaceutical research institute member executive senior vice president new product development glaxosmithkline plc committee present chief scientific officer corporate staff company president pharmaceutical research institute division company elliott sigal md phd vice president applied genomics pharmaceutical research senior vice president global clinical pharmaceutical institute division company senior vice president early development pharmaceutical research institute member discovery applied technology pharmaceutical research institute division executive committee company senior vice president drug discovery exploratory development pharmaceutical research institute division company present senior vice president global clinical pharmaceutical development pharmaceutical research institute division company john l skule present senior vice president corporate environmental affairs senior vice president corporate environmental affairs corporate staff company corporate staff member executive committeedavid l zabor vice president financial analysis medical devices corporate vice president controller corporate staff staff company vice president assistant treasurer corporate staff company vice president finance technical operations worldwide medicines group division company vice president financial planning corporate staff company vice president acting controller corporate staff company present vice president controller corporate staff company part ii item market registrant 's common stock related stockholder matters market prices bristolmyers squibb common preferred stocks traded new york stock exchange pacific exchange inc symbols bmy bmypr quarterly summary high low market prices presented common high low high low first quarter second quarter third quarter fourth quarter preferred company 's preferred stock traded high low fourth quarter quarters first second third quarters trades company 's preferred stock preferred stock pays quarterly dividend per share holders common stock approximate number record holders common stock december number record holders based upon actual number holders registered books bristolmyers squibb date include holders shares street names persons partnerships associations corporations entities identified security position listings maintained depository trust companies voting securities principal holders reference made proxy statement filed april respect voting securities principal holders incorporated herein reference made part hereof response information required item dividends dividends declared per share common preferred first quarter second quarter third quarter fourth quarter december board directors company declared quarterly dividend per share common stock company paid february shareholders record january item selected financial data fiveyear financial summaryincome statement data millions except per share data net sales cost products sold marketing selling administrative advertising product promotion research development acquired inprocess research development provision restructuring items litigation settlement charge gain sales businessesproduct lines income expense net earnings continuing operations minority interest income taxes provision income taxes minority interest net taxes earnings continuing operations earnings continuing operations per common share basic diluted average common shares outstandingbasic average common shares outstandingdiluted dividends paid common preferred stock dividends declared per common share financial position data december total assets longterm debt stockholders ' equity includes asset impairment charge million company 's investment imclone also includes interest expense million million million million million years ended december respectively includes minority interest expense income unconsolidated affiliates financial position data relates company 's assets liabilities including discontinued operations years item management 's discussion analysis financial condition results operations recent developments company restated previously issued financial statements three years ended december including corresponding interim periods quarterly periods ended march june restatement affected periods prior impact restatement prior periods reflected adjustment opening retained earnings january restatement reported amendment company 's annual report year ended december amendments company 's quarterly reports form qa quarterly periods ended march june company experienced substantial buildup wholesaler inventories us pharmaceuticals business several years primarily buildup primarily due sales incentives offered company wholesalers incentives generally offered towards end quarter order incentivize wholesalers purchase products amount sufficient meet company 's quarterly sales projections established company 's senior management april company disclosed substantial buildup developed subsequently undertook plan work orderly fashion wholesaler inventory levels late october based review consideration previously disclosed buildup wholesaler inventories company 's us pharmaceuticals business incentives offered certain wholesalers advice company 's independent auditors pricewaterhousecoopers llp company determined required restate sales earnings correct errors timing revenue recognition certain sales certain us pharmaceuticals wholesalers since time company undertook analysis transactions incentive practices us pharmaceuticals wholesalers result analysis company determined certain sales two largest wholesalers us pharmaceuticals business accounted consignment model rather recognizing revenue transactions upon shipment based part relationship amount incentives offered wholesalers amount inventory held wholesalers determination involved evaluation variety ofcriteria number complex accounting judgments following determination restate sales earnings matters described company also determined would correct certain historical accounting policies conform accounting us generally accepted accounting principles gaap certain known errors made application gaap previously recorded case company believed amount error material company 's consolidated financial statements addition part restatement process company investigated accounting practices certain areas involve significant judgments determined restate additional items respect company concluded errors made application gaap including certain revisions inappropriate accounting senior management set aggressive targets company 's businesses errors inappropriate accounting corrected restatement arose least part period unrealistic expectations consequent overestimation anticipated performance certain company 's products programs connection audits restatement previously issued annual financial statements company 's consolidated financial statements year ended december company 's independent auditors pricewaterhousecoopers llp identified communicated company audit committee two material weaknesses defined standards established american institute certified public accountants relating company 's accounting public financial reporting significant matters initial recording management review oversight certain accounting matters last year company searched hired new chief financial officer outside company restaffed controller position created position chief compliance officer changed leadership pharmaceuticals group response wholesaler inventory buildup matters identified restatement adjustments direction audit committee last year senior management directed company dedicate resources take steps strengthen control processes procedures order identify rectify past accounting errors prevent recurrence circumstances resulted need restate prior period financial statements company also revised budgeting process emphasize bottomup approach contrast topdown approach company implemented review certification process annual quarterly reports securities exchange act amended well processes designed enhance monitoring wholesaler inventories addition company process expanding business risks disclosure group includes senior management including chief executive officer chief financial officer taking number additional steps designed create open environment communications flow information throughout company company continues identify implement actions improve effectiveness disclosure controls procedures internal controls including plans enhance resources training respect financial reporting disclosure responsibilities review actions audit committee independent auditors company 's accounting certain sales two largest wholesalers us pharmaceuticals business consignment model discussed net sales throughout following management 's discussion analysis financial condition results operations referenced amounts prior periods prior period comparisons reflect balances amounts restated basis summary company reported annual global sales billion sales increased prior year level reflecting volume increases offset net price declines net impact foreign exchange fluctuations earnings continuing operations million per share basic diluted basis compared million basic earnings per share diluted earnings per share several items affected comparability results discussed earnings addition items earnings adversely affected generic competition us several key pharmaceutical products increase interest expense due billion debt issued third quarter finance dupont imclone transactions partially offsetting decline favorable impact dupont operations company two blockbuster products sales billionpravachol plavix pravachol sales grew billion plavix sales grew billion addition two products company product lines million annual sales including products million annual sales four annual sales excess million company 's financial position remains strong december company held almost billion cash time deposits marketable securities approximately billion cash time deposits marketable securities held company 's foreign subsidiaries repatriation cash us would require additional tax provisions reflected consolidated financial statements discussion matter see critical accounting policiesincome taxes cash provided operating activities billion working capital healthy billion company paid dividends approximately billion provided dividend yield consistent company 's mission extend enhance human life developing highestquality products company invested billion research development growth research development dedicated pharmaceutical products billion increased pharmaceutical sales compared compound annualized growth pharmaceutical research development spending past five years research development highlights included us food drug administration fda regulatory approval new chemical entity nce abilify new antipsychotic medicationindicated treatment schizophrenia us company markets abilify jointly otsuka america pharmaceutical eight fda regulatory approvals following life cycle management lcm indications videx ec daily tablet sustiva daily tablet plavix acute coronary syndrome avaproaprovel diabetic nephropathy glucovance combination thiazolidinediones pravachol pediatrics zerit xr prolonged release capsule tequin uncomplicated skin skin structure indication seven regulatory filings achieved including us european submissions nce atazanavir six lcm supplemental filings serzone pediatrics taxol firstline metastatic breast cancer pravachol pediatrics monopril pediatrics platinol hepatocellular carcinoma glucophage xr mg reduced mass tablet patent expirations us several key products including glucophage ir taxol buspar significant impact company 's financial performance us patents expected expire next three years include patent cefzil december one several patents relating plavix july addition use patent paraplatin expire april hatchwaxman data protection expire glucophage xr october glucovance july expiry dates could extended sixmonths pediatric extension upon completion acceptance pediatric studies fda advance expiration company received sixmonth pediatric extension composition matter patent monopril expected expire june composition matter patent serzone expected expire september patent covering formulation videx ec expected expire may except respect plavix discussed item legal proceedings part note litigation matters consolidated financial statements company believes single patent license material importance relation business whole net sales sales billion increase prior year compared sales increases respectively sales include approximately million million respectively sales related products acquired part dupont acquisition completed october domestic sales decreased million compared increase million international sales increased million foreign exchange significant impact compared increase million foreign exchange unfavorably impacted sales general company 's business seasonal information us pharmaceuticals prescriber demand reference made table sets forth comparison changes net sales estimated total retail mail order customers prescription growth certain company 's primary care pharmaceutical products composition net increase sales follows foreign exchange volume selling prices net increase sales significant portion company 's us pharmaceuticals sales made wholesalers company experienced substantial buildup wholesaler inventories us pharmaceuticals business several years primarily buildup primarily due sales incentives offered company wholesalers including discounts buyins anticipation price increases extended payment terms certain us pharmaceuticals wholesalers incentives generally offered towards end quarter order incentivize wholesalers purchase products amount sufficient meet company 's quarterly sales projections established company 's senior management timing company 's recognition revenue sales wholesalers differs wholesaler period historically company recognized revenue sales upon shipment product customers gaap revenue recognized substantially risks rewards ownership transferred case sales made wholesalers result incentives excess wholesaler 's ordinary course business inventory level time understanding agreement course dealing consistent business practice company would extend incentives based levels excess inventory connection future purchases time incentives would cover substantially vary directly wholesaler 's cost carrying inventory excess wholesaler 's ordinary course business inventory level substantially risks rewards ownership transfer upon shipment accordingly sales accounted using consignment model determination sales wholesaler meet foregoing criteria involves evaluation variety factors number complex judgments consignment model company recognize revenue upon shipment product rather upon shipment product company invoices wholesaler records deferred revenue gross invoice sales price classifies inventory held wholesalers consignment inventory company 's cost inventory company recognizes revenue net discounts rebates estimated sales allowances accruals returns consignment inventory longer subject incentive arrangements later inventory sold wholesalers ' customers firstin firstout fifo basis additional discussion company 's revenue recognition policy see note accounting policies consolidated financial statements company restated previously issued financial statements period second quarter correct timing revenue recognition certain previously recognized us pharmaceuticals sales cardinal health inc cardinal mckesson corporation mckesson two largest wholesalers company 's us pharmaceuticals business based application criteria described recorded error time shipment accounted using consignment model company determined shipments product cardinal shipments product mckesson met consignment model criteria set forth july july respectively case continuing end period thereafter accordingly consignment model required applied shipments prior respective periods company recognized revenue respect sales cardinal mckesson upon shipment product although thecompany generally views approximately one month supply desirable level wholesaler inventory goingforward basis level wholesaler inventory representative industry average applying consignment model sales cardinal mckesson company defined inventory excess wholesaler 's ordinary course business inventory level inventory two weeks three weeks supply respectively based levels inventory cardinal mckesson required used basis negotiation incentives granted result restatement adjustment net sales reduced million million million respectively increased million six months ended june corresponding effect earnings continuing operations minority interest income taxes reduction million million million respectively increase million six months ended june separately discussion march company entered distribution agreement mckesson provision warehousing order fulfillment services company 's oncology therapeutics network otn specialty distributor anticancer medicines related products prior restatement company recorded error sales company 's products agreement upon shipment product mckesson company restated previously issued financial statements account sales consignment model resulting effect net sales earnings continuing operations minority interest income taxes reduction million million respectively increase million million respectively six months ended june december company 's aggregate cost pharmaceutical products held cardinal mckesson accounted using consignment model accordingly reflected consignment inventory company 's consolidated balance sheet approximately million million million respectively approximately million million december respectively related otn deferred revenue recorded gross invoice sales price related inventory pharmaceutical products accounted using consignment model approximately million million million december respectively approximately million million december respectively related otn result restatement application consignment model approximately million sales calculated net customary early pay cash discounts reversed period approximately million recognized inventory held cardinal mckesson worked approximately million projected recognized significant portion expected recognized first quarter corresponding effect earnings continuing operations minority interest income taxes increase million corresponding projected effect earnings continuing operations minority interest income taxes increase approximately million significant portion expected recognized first quarter sales cardinal mckesson represented approximately us pharmaceuticals net sales respectively company determined although sales incentives offered wholesalers buildup inventories wholesalers consignment model criteria discussed met accordingly company recognized revenue products shipped wholesalers company estimates inventory pharmaceutical products held us pharmaceuticals wholesalers excess approximately one month supply case company 's exclusive products approximately one half months supply case plavix avapro marketed company 's alliance sanofisynthelabo approximately two months supply case company 's nonexclusive products range approximately million million december company 's estimates inventories held wholesalers based projected prescription demandbased sales products well company 's analysis thirdparty information including information obtained certain wholesalers respect inventory levels sellthrough customers thirdparty market research data company 's internal information company 's estimates subject inherent limitations estimates rely thirdparty data certain thirdparty information form estimates reflect limitations april company disclosed substantial buildup wholesaler inventories us pharmaceuticals business developed subsequently undertook plan work orderly fashion wholesaler inventory levels facilitate orderly workdown company 's plan included continuing offer sales incentives reduced levels certain wholesalers respect mckesson cardinal company entered agreements orderly workdown provide wholesalers make specified levels purchases company offer specified levels incentives workdown period company expects orderly workdown inventories pharmaceutical products held us pharmaceuticals wholesalers substantially completed end company also expects consignment model criteria longer met respect company 's us pharmaceuticals sales cardinal mckesson abovementioned sales related otn end december company 's aggregate cost pharmaceutical products held cardinal mckesson accounted using consignment model accordingly reflected consignment inventory company 's consolidated balance sheet approximately million december deferred revenue recorded gross invoice sales price related inventory approximately million including approximately million related otn company estimates based data noted inventory pharmaceutical products held us pharmaceuticals wholesalers excess approximately one month supply case company 's exclusive products approximately one half months supply case plavix avapro marketed company 's alliance sanofisynthelabo approximately two months supply case company 's non exclusive products range approximately million level supply million excess level supply december estimate subject inherent limitations noted company expects account certain pharmaceutical sales relating otn using consignment model abovementioned agreement mckesson expires company 's financial results prior period quarterly comparisons affected buildup orderly workdown wholesaler inventories well application consignment model certain sales certain wholesalers addition respect sales accounted using consignment model company 's financial results prior period quarterly comparisons affected fluctuations buying patterns wholesalers including effect incentives offered corresponding changes inventory levels maintained wholesalers wholesaler buying patterns wholesaler inventory levels may reflect underlying prescriber demand information us pharmaceuticals prescriber demand reference made table sets forth comparison changes net sales estimated total retail mail order customers prescription growth certain company 's primary care pharmaceutical products company expects consignment model longer applied respect sales cardinal mckesson buying patterns fluctuations inventory levels wholesalers effect company 's financial results prior period quarterly comparisonsearnings earnings continuing operations minority interest income taxes increased million million earnings continuing operations million consistent million earned basic earnings per share continuing operations flat prior year diluted earnings per share continuing operations increased prior year earnings continuing operations minority interest income taxes decreased million million earnings continuing operations decreased million million basic earnings per share continuing operations decreased diluted earnings per share continuing operations decreased net earnings margins continuing operations decreased years ended december company recorded several items affected comparability results periods presented herein set forth following table discussion items see note alliances investments note restructuring items note acquisitions divestitures note discontinued operations consolidated financial statements dollars millions acquired inprocess research development litigation settlement charge asset impairment charge imclone restructuring items gain sales businessesproduct lines income tax benefit items settlement prior year tax matters million restructuring reversal million million restructuring expense included cost products sold respectively million accelerated depreciation research facilities included research development million deductions customer chargebacks related abandoned product lines included reduction net sales company also incurred million costs related dupont acquisition million included cost products sold gross margin percentages respectively gross margins adversely impacted generic competition change product mix effective income tax rate earnings continuing operations minority interest income taxes compared effective income tax rate includes income tax benefit million due settlement certain prior year tax matters determination company expected settlement ongoing tax litigation partially offset million valuation allowances comprised million related certain state net deferred tax assets million related certain state tax net operating loss carryforwards million related foreign tax credit carryforwards company currently believe likely realized future low effective income tax rate results primarily lower pretax income us caused writeoff acquired inprocess research development well proportionately greater income earned lowtax jurisdictions expenses total costs expenses percentage sales compared cost products sold percentage sales increased last three years compared principally due increased sales lowermargin products otn decline highermargin glucophage ir taxol buspar sales result introduction generic products us cost products sold includes million reversal prior period reserves inventory writeoffs related actions cancelled million million restructuring expense respectively advertising promotion expenses decreased slightly million million primarily result reduced spending metformin franchise vaniqa partially offset abilify product launch expenses increased support plavix avapro us advertising promotion expenses decreased million result lower spending taxol buspar percentage sales advertising promotion expenses decreased marketing selling administrative expenses percentage sales increased slight increase mainly due higher sales force expenses result addition medical imaging business acquired october part dupont acquisition marketing selling administrative expenses percentage sales decreased primarily result costefficiencies reduction sales force expenses company 's investment research development totaled million increase percentage sales increased compared research development included million accelerated depreciation research facilities research development spending dedicated pharmaceutical products increased pharmaceutical sales compared respectively lower growth research development spending consistent new priorities company announced ensure company fully realize value research development pipeline new priorities include rebalancing drug discovery development increase support company 's full latestage development pipeline also include devoting greater resources ensuring successful nearterm productlaunches increasing company 's efforts inlicensing opportunities consistent priorities company expects midtohigh teens increase percentage basis spending advertising promotion charges related acquired inprocess research development million primarily related milestone payments imclone erbitux million milestone payable imclone million expensed acquired inprocess research development first quarter remaining million recorded additional equity investment eliminate income statement effect portion milestone payment company economic claim ownership interest imclone acquired inprocess research development charge million including million related dupont acquisition million attributable imclone equity investment addition acquired inprocess research development include charges million million million respectively licensing payments related products yet approved marketing restructuring programs implemented downsize realign streamline operations order increase productivity reduce operating expenses rationalize company 's manufacturing network research facilities programs include costs termination approximately employees including research manufacturing administrative personnel addition company eliminated nonstrategic research efforts consolidated research facilities us actions restructuring program expected substantially complete late result actions company expects annual benefit earnings continuing operations minority interest income taxes approximately million future years restructuring programs implemented downsize realign streamline operations order increase productivity reduce operating expenses rationalize company 's manufacturing network research facilities programs include costs termination approximately employees including sales force manufacturing administrative research personnel addition contract sales force terminated company also exited nutritional business eastern europe pharmaceutical production facility us research facility france actions restructuring program expected substantially complete early result actions company expects annual benefit earnings continuing operations minority interest income taxes approximately million future years portion realized restructuring programs implemented downsize realign streamline operations order increase productivity reduce operating expenses rationalize company 's manufacturing network research facilities program approximately employees terminated including sales force manufacturing administrative personnel addition company also exited production facility us certain international operations convatec research facility japan result actions company expects annual benefit earnings continuing operations minority interest income taxes approximately million future years majority realized actions substantially complete additional information restructuring see note restructuring items consolidated financial statements business segments company operates three reportable segmentspharmaceuticals nutritionals healthcare percent company 's sales segment follows total sales pharmaceuticals nutritionals healthcare pharmaceuticals worldwide pharmaceuticals sales decreased million reflecting price decline volume increase foreign exchange impact domestic sales declined million primarily due generic competition us glucophage ir taxol buspar partially offset increased sales plavix addition products acquired dupont acquisition completed october addition decrease domestic pharmaceutical sales impacted buildup prior period inventory levels us wholesalers accounted consignment model subsequent workdown international sales increased million foreign exchange significant impact primarily due increased sales pravachol plavix europe taxol japan addition products acquired dupont acquisition approximately million sales calculated net customary early pay cash discounts recognized year ended december reversed prior years worldwide pharmaceuticals sales increased million reflecting price increase volume increase partially offset decrease foreign exchange domestic sales increased million primarily due strong growth plavix pravachol tequin glucophage ir partially offset decreased sales taxol buspar due generic competition addition domestic sales increase reflects favorable impact previously disclosed buildup inventory levels us wholesalers accounted consignment model international sales increased million including decrease foreign exchange result increased sales pravachol europe plavix internationally taxol japan partially offset decreased sales capoten key pharmaceutical products sales include following sales pravachol cholesterollowering agent company 's largestselling product increased million domestic sales increased million international sales increased foreign exchange favorable impact million october fda approved new indication use treating pediatric patients heterozygous familial hypercholesterolemia additionally sixmonth exclusivity extension granted april pravachol sales increased million sales otn specialty distributor anticancer medicines related products increased million million sales plavix platelet aggregation inhibitor increased million driven part positive results cure clopidogrel unstable angina prevent recurrent ischemic events study addition american college cardiology american heart association issued updated guidelines adding plavix standard therapy including aspirin treat people acute coronary syndrome sales avapro angiotensin ii receptor blocker treatment hypertension increased million sales avapro plavix increased million million respectively avapro plavix cardiovascular products launched alliance bristolmyers squibb sanofisynthelabo glucophage franchise sales decreased million compared increase million glucophage ir leading branded oral medication treatment noninsulin dependent type diabetes saw sales decrease million decline glucophage ir due introduction generic metformin us early glucophage ir sales increased million glucovance oral combination drug glucophage xr extended release tablets sales million million respectively compared sales million million respectively fda approved metaglip combination glipizide metformin hci tablets initial drug therapy people type diabetes sales metaglip million sales taxol decreased million international sales increased foreign exchange favorable impact million led strong sales japan france domestic sales decreased million due generic competition taxol sales decreased million sales paraplatin used combination therapy treatment ovarian cancer increased million paraplatin sales decreased million sales zerit antiretroviral drug used treatment hiv decreased million primarily result decreased demand due adverse side effects zerit sales decreased million monopril secondgeneration angiotensin converting enzyme ace inhibitor increased sales reaching million monopril sales increased million sales sustiva coumadin products acquired dupont october million million respectively total us prescriptions coumadin decreased sales videxvidex ec antiretroviral agent increased million videxvidex ec sales increased million sales serzone treatment depression decreased million primarily result labeling change indicating serious side effect product serzone sales increased million following table sets forth comparison reported net sales changes estimated total retail mail order customers prescription growth certain company 's us primary care pharmaceutical products estimated prescription growth amounts based thirdparty data significant portion company 's domestic pharmaceutical sales made wholesalers changes reported net sales differs prescription growth change net sales may reflect underlying prescriber demand change change change change change change us us total us us total us us total net sales prescriptions net sales prescriptions net sales prescriptions pravachol glucophageir plavix avapro monopril serzone cefzil buspar earnings minority interest income taxes million million respectively increase mainly due lowered earnings result writeoff million acquired inprocess research development earnings unfavorably affected higher sales lower margin products including products otn business full year impact generic competition glucophage ir taxol buspar us earnings minority interest income taxes million decreased million primarily due acquired inprocess research development expenses together impact generic competition taxol buspar us nutritionals nutritionals sales comparable prior year level billion reflecting increase due price offset decrease due volume decrease due foreign exchange worldwide infant formula sales decreased million primarily specialty infant formula business worldwide sales enfamil company 's largestselling infant formula million consistent million mead johnson continues leader us infant formula markets worldwide children 's nutritionals sales increased including decrease foreign exchange million million result increase sales enfagrow primarily across pacific region million sales enfagrow increased million nutritionals sales flat prior year billion reflecting increase due price offset decrease due volume decrease due foreign exchange worldwide infant formula sales increased including decrease foreign exchange million primarily due increase sales enfamil worldwide adult nutritional sales decreased million million result divestiture viactiv business earnings minority interest income taxes nutritionals segment decreased million million result increased promotional spending sales force expense related enfamil product line earnings minority interest income taxes nutritionals segment increased million million primarily due copromotion income cefzil pharmaceuticals segment lower advertising promotion spending viactiv healthcare healthcare segment includes convatec medical imaging business consumer medicines us japan sales healthcare segment increased million including million sales medical imaging purchased october part dupont acquisition healthcare sales increase result increase due volume increase changes selling prices foreign exchange net impact sales change sales segment increased million million healthcare sales increase result increase due volume increase changes selling prices decrease due foreign exchange healthcare sales business follows change dollars millions convatec medical imaging na na consumer medicines total healthcare increase convatec sales due increase sales ostomy products million strong growth wound care products increased million foreign exchange contributed sales increase increase convatec sales due increase sales ostomy products million strong growth wound care products increased million foreign exchange negative effect sales steady decline sales consumer medicines million million primarily result lower demand analgesics keri products us earnings minority interest income taxes healthcare segment increased million million primarily due strong growth convatec business addition medical imaging business october earnings minority interest income taxes segment increased million million primarily due addition medical imaging business geographic areas company 's products available virtually every country world largest markets us france japan germany spain canada italy sales us decreased primarily due generic competition us glucophage ir taxol buspar lesser extent buildup prior period inventory levels us wholesalers accounted consignment model subsequent workdown decrease partially offset increase plavix sales addition products acquired dupont dupont pharmaceuticals us sales million sales us increased primarily due growth plavix pravachol glucophage ir offset declines taxol buspar dupont pharmaceuticals us sales million company 's acquisition dupont completed october information us pharmaceuticals prescriber demand reference made table sets forth comparison changes net sales estimated total retail mail order customers prescription growth certain company 's primary care pharmaceutical products sales europe mideast africa increased including increase foreign exchange result strong growth pravachol france united kingdom plavix spain addition dupont products throughout region dupont sales region million sales europe mideast africa increased including decrease foreign exchange primarily due growth pravachol france italy sales western hemisphere countries decreased including decrease foreign exchange unfavorable impact foreign exchange primarily brazil argentina underlying sales growth primarily due increased sales plavix canada increased sales nutritional products mexico sales western hemisphere countries decreased including decrease foreign exchange unfavorable impact foreign exchange mainly brazil underlying sales growth primarily driven increased sales nutritional products mexico sales pacific region increased including decrease foreign exchange products strong growth included taxol paraplatin japan nutritional products china indonesia pacific region sales decreased including decrease foreign exchange underlying sales growth driven primarily strong growth taxol japan nutritional products philippines thailand chinafinancial position cash cash equivalents time deposits marketable securities totaled approximately billion december compared billion december approximately billion cash cash equivalents time deposits marketable securities held company 's foreign subsidiaries repatriation cash us would require additional tax provisions reflected consolidated financial statements discussion matter see critical accounting policiesincome taxes working capital decreased billion december billion december primarily result decrease cash cash equivalents increase commercial paper outstanding partially offset lower deferred revenue consigned inventory cash cash equivalents time deposits marketable securities conversion workingcapital items expected fund nearterm operations cash cash equivalents time deposits marketable securities december denominated primarily us dollar instruments nearterm maturities average interest yield cash cash equivalents december respectively interest yields time deposits marketable securities averaged respectively shortterm borrowings longterm debt december denominated primarily us dollars also include japanese yen longterm debt million majority company 's debt fixed rate company entered fixed floating interest rate swaps billion longterm debt interest expense million million million respectively average interest rate shortterm borrowings current installments longterm debt case december respectively company 's longterm credit ratings moody 's standard poor 's credit rating agencies reduced aaaaaa aa aa respectively december moody 's placed company 's longterm shortterm debt ratings review possible downgrade since company held discussions moody 's provided additional information requested facilitate review march moody 's confirmed prime shortterm ratings company company 's longterm ratings remain review possible downgrade net cash provided operating activities approximately billion billion billion decrease attributable lower net earnings income tax cash outflows billion primarily related taxes gain arising sale clairol business cash flow operations also included pension contributions million million million respectively cash provided operations primarily used past three years pay dividends billion repurchase million shares cost billion company also invested billion past three years capital expansion improve plant efficiency maintain superior research facilities company purchased million shares common stock cost million bringing total shares acquired since share repurchase program 's inception million shares company repurchased million million shares common stock cost million million respectively share repurchase program authorizes company purchase common stock time time open market private transactions market conditions permit program intended reduce increase shares outstanding option exercises obtain shares general corporate purposes employment levels december decreased prioryear levels result workforce reductions associated restructuring activities overall attrition dividends declared per common share respectively december company declared quarterly dividend per common share indicated dividend full year per share contractual obligations obligations expiring period total dollars millions shortterm borrowings longterm debt operating leases standby letters credit performance bond guarantees total payments included shortterm borrowings company 's consolidated balance sheet excludes million expiry date discussion contractual obligations reference made note shortterm borrowings longterm debt note financial instruments note leases consolidated financial statements march company imclone revised agreement reducing total payment million billion pursuant agreement company paid imclone million million million pay aggregate million upon achievement two milestones discussion company 's agreement imclone see note alliances investments consolidated financial statements recently issued accounting standards january financial accounting standards board fasb issued interpretation consolidation variable interest entities fin fin requires variable interest entity consolidated company company subject majority risk loss variable interest entity 's activities entitled receive majority entity 's residual returns fin also requires disclosures variable interest entities company required consolidate significant variable interest consolidation requirements fin apply immediately variable interest entities created january existing entities first fiscal year interim period beginning june certain disclosure requirements apply financial statements issued january regardless variable interest entity established company process assessing impact pronouncement consolidated financial statements based preliminary analysis impact fin company believes reasonably possible imclone could meet criteria considered variable interest entity relation company accordingly company included required transitional disclosures fin note alliances investments consolidated financial statements december fasb issued sfas accounting stockbased compensationtransition disclosure sfas amends sfas accounting stockbased compensation provide alternative methods transition voluntary change fair value based method accounting stockbased employee compensation addition sfas amends disclosure requirements sfas require prominent disclosures annual interim financial statements method accounting stockbased employee compensation effect method used reported results provisions sfas effective financial statements year ended december sfas material impact company 's consolidated financial statements adoption standard require company change company plan change fair value based method accounting stockbased compensation november fasb issued interpretation guarantor 's accounting disclosure requirements guarantees including indirect guarantees indebtedness others fin fin requires guarantor recognize liability inception guarantee fair value obligation undertaken issuing guarantee include detailed disclosure respect guarantees types contracts company enters meet scope interpretation financial performance standby letters credit behalf whollyowned subsidiaries fin effective guarantees issued modified december initial adoption accounting pronouncement material effect company 's consolidated financial statements june fasb issued sfas accounting exit disposal activities effective exit disposal activities initiated december sfas addresses issues regarding recognition measurement reporting costs associated exit andor disposal activities including restructuring activities currently accounted pursuant guidance emerging issues task force eitf set forth eitf issue liability recognition certain employee termination benefits costs exit activity including certain costs incurred restructuring sec set forth staff accounting bulletin restructuring impairment charges initial adoption accounting standard material effect company 's consolidated financial statements april fasb issued sfas superseded sfas requirement aggregate gains losses extinguishment debt classify material extraordinary item net related income tax effect result criteria accounting principles board opinion used classify gains losses sfas also amends sfas require certain lease modifications economic effects similar sale leaseback transactions accounted manner saleleaseback transactions initial adoption standard materially affect company 's consolidated financial statements company adopted sfas goodwill intangible assets sfas accounting impairment disposal long lived assets see note accounting policies accompanying consolidated financial statements information june fasb issued sfas accounting asset retirement obligations sfas fair value liability asset retirement obligation must recognized period incurred reasonable estimate fair value made associated asset retirement costs capitalized part carrying amount longlived asset provisions sfas effective financial statements fiscal years beginning june initial adoption standard expected material impact company 's consolidated financial statements retirement benefits plan description company certain subsidiaries defined benefit pension plans defined contribution plans regular fulltime employees principal defined benefit pension plan bristolmyers squibb retirement income plan principal defined contribution plan bristolmyers squibb savings investment program approximately total company defined benefit pension plan assets liabilities held us plans assets us plans held single trust common asset allocation unless specified otherwise references section total company plans us plans together international plans benefits company 's defined benefit pension plans based primarily years credited service participants ' compensation assets company 's defined benefit plans consist primarily equity fixedincome securities december fair market value plan assets company 's defined benefit plans decreased million million december us plans assets allocated equity securities compared end fixed income securities compared end real estate investments change end bristolmyers squibb common stock represented less assets us plans end company provides comprehensive medical group life benefits substantially us retirees elect participate company 's comprehensive medical group life plans asset allocation postretirement plans identical asset allocation described us defined benefit pension plans accrual accounting significant assumptions consistent gaap requirements set forth sfas employers ' accounting pensions company accounts pension benefits using theaccrual method recognizing pension expense payment benefits retirees accrual method accounting pension benefits necessarily requires actuarial assumptions concerning future events determine amount timing benefit payments company 's key assumptions used calculating cost pension benefits discount rate rate compensation increase expected long term rate return plan assets company consultation actuaries evaluates key actuarial assumptions assumptions used calculating cost pension benefits retirement turnover mortality rates based expectations actual experience appropriate determines assumptions december year calculate liability information date pension expense following year depending assumptions used pension expense could vary within range outcomes material effect reported earnings addition assumptions materially affect accumulated benefit obligations future cash funding actual results given year may differ estimated economic factors assumed discount rate used company determining future pension obligations us plans based indices aa aaarated corporate bonds indices high quality corporate bonds selected reflect weightedaverage remaining period benefit payments assumed rate compensation increase used company determining future pension obligations reflects estimate change actual future compensation levels due general price levels productivity seniority factors net pension expense company 's defined benefit pension plans included earnings minority interest income taxes million compared million included million us curtailmentsettlement loss us plans pension expense determined using assumed discount rate assumed rate compensation increase accumulated benefit obligation december us plans determined using assumed discount rate assumed discount rate used determining us plans pension expense reduced expense would increased approximately million assumed rate compensation increase used determining us plans pension expense reduced expense would decreased approximately million assumed discount rate used determining accumulated benefit obligation december reduced accumulated benefit obligation would increased million determining expected longterm rate return plan assets company evaluates allocation assets expected returns various asset classes company evaluates shortterm market volatility context longterm nature pension commitments us plans ' pension expense determined using expected longterm rate return plan assets expected longterm rate return plan assets used determining us plans pension expense reduced expense would increased million actual rates return earned us plan assets last ten years follows year return year return discussed accounting principles provide differences expected actual returns recognized average future service employees december company lowered assumed discount rate reflect decline yields high quality corporate bonds assumed rate compensation increase reflect expectations lower inflation future consistent reduction assumed discount rate reduction assumed discount rate increased present value future benefit obligations accordingly effect increasing us plans pension expense contrast reduction assumed rate compensation increase decreased present value benefit obligations accordingly effect decreasing us plans pension expense december company lowered assumed discount rate us plans assumed rate compensation increase us plans aggregate revisions effect increasing present value future benefit obligations accordingly effect increasing pension expense addition company revised based change expectations future terminations retirements retirement turnover assumptions revision effect decreasing present value future benefit obligations accordingly effect decreasing pension expense course last several years global equity markets experienced negative returns negative equity market returns compounded market decline sp declined company evaluates market conditions determining expected longterm rate return plan assets company reduced expected rate return us plans assets december reduction expected result higher pension expense approximately million company expects net pension expense defined benefit pension plans included earnings minority interest income taxes approximately million higher reflecting among things decreases assumed discount rate expected longterm rate return outlined decrease value assets company 's defined benefit pension plans company used assumed discount rates expected longterm rates return plan assets calculating cost postretirement benefits calculating cost pension benefits delayed recognition actuarial gains losses december unrecognized net actuarial losses company 's defined benefit plans million million respectively based fair market value plan assets unrecognized net actuarial losses reflect decline fair market value plan assets reduction theweightedaverage discount rate sfas provides delayed recognition actuarial gains losses including amounts arising changes estimated plan benefit obligations due changes assumed discount rate differences actual expected returns plan assets assumption changes sfas requires unrecognized net actuarial gain loss determined based marketrelated value plan assets differs fair market value calculated value recognizes changes fair value systematic rational manner five years amortized pension income expense year extent unrecognized net actuarial loss gain exceeds greater projected benefit obligation marketrelated value plan assets beginning year net gains losses recognized pension income expense prospectively period approximates average remaining service period active employees expected receive benefits plans approximately years extent offset losses gains subsequent years december unrecognized net actuarial loss determined based marketrelated value plan assets million amount exceed greater projected benefit obligation marketrelated value plan assets beginning year accordingly required amortized pension expense december unrecognized net actuarial loss determined based marketrelated value plan assets million amount exceeded greater projected benefit obligation market related value plan assets million unless offset future unrecognized gains higher discount rates higher expected returns plan assets amortization million unrecognized loss expected increase pension expense following ten years approximately million per year amount reflected expected increase pension expense approximately million compared event fair market value pension plan assets particular plan less accumulated benefit obligation plan yearend gaap may require additional minimum liability circumstances reduction stockholders ' equity establishment intangible asset december fair market value company 's defined benefit pension plan assets million related accumulated benefit obligation million december fair market value company 's defined benefit pension plans assets million related accumulated benefit obligation million company recognized additional minimum liability million december offset creation million intangible asset million charge comprehensive income included stockholders ' equity company also recognized additional minimum liability approximately million million december respectively plan funding company 's funding policy defined benefit plans contribute amounts provide current service fund past service liability company contributed defined benefit plans million million million respectively recent decline global equity markets resulted decrease value assets company 's pension plans decline expected adversely affect company 's related accounting results future periods higher pension expense increased cash funding requirements company 's contribution defined contribution plans based employee contributions level company match company contributed principal defined contribution plan million million million respectively critical accounting policies company prepares financial statements accordance gaap preparation financial statements conformity gaap requires use estimates assumptions affect reported amounts assets liabilities including disclosure contingent assets contingent liabilities date financial statements reported amounts revenue expenses reporting period company 's critical accounting policies important company 's financial condition results operations require difficult subjective complex judgments part management application often result need make estimates effect matters inherently uncertain uncertainty factors surrounding estimates judgments used preparation consolidated financial statements actual results may vary estimates company believes following represent critical accounting policies summary company 's significant accounting policies including critical accounting policies discussed see note accounting policies consolidated financial statements management company 's independent accountants discussed company 's critical accounting policies audit committee board directors revenue recognition company 's accounting policy revenue recognition substantial impact reported results relies certain estimates require difficult subjective complex judgments part management company recognizes revenue sales upon shipment product customers except case certain transactions us pharmaceuticals wholesalers accounted using consignment model gaap revenue recognized substantially risks rewards ownership transferred case sales made wholesalers result incentives excess wholesaler 's ordinary course business inventory level time understanding agreement course dealing consistent business practice company would extend incentives based levels excess inventory connection future purchases time incentives would cover substantially vary directly wholesaler 's cost carrying inventory excess wholesaler 's ordinary course business inventory level substantially risks rewards ownership transfer upon shipment accordingly sales accounted using consignment model determination sales wholesaler meet foregoing criteria involves evaluation variety factors number complex judgments consignment model company recognize revenue upon shipment product rather upon shipment product company invoices wholesaler records deferred revenue gross invoice sales price classifies inventory held wholesalers consignment inventory company 's cost inventory company recognizes revenue net discounts rebates sales allowances accruals returns involve significant estimates judgments consignment inventory longer subject incentive arrangements later inventory sold wholesalers ' customers firstin firstout fifo basis company 's estimates inventory wholesalers deferred revenue consigned inventory based projected prescription demandbased sales products well company 's analysis thirdparty information including information obtained certain wholesalers respect theirinventory levels sellthrough customers thirdparty market research data company 's internal information company 's estimates subject inherent limitations estimates rely thirdparty data certain thirdparty information form estimates reflect limitations acquired inprocess research development fair value inprocess research development acquired business combination acquired iprd determined independent appraisal based present value research project 's projected cash flows utilizing income approach consistent aicpa practice aid assets acquired business combinations used research development activities focus software electronic devices pharmaceutical industries future cash flows predominately based net income forecast project consistent historical pricing margins expense levels similar products revenues estimated based relevant market size growth factors expected industry trends individual project life cycles life research project 's underlying patent determining fair value research project expected revenues first adjusted technical risk completion resulting cash flows discounted rate approximating company 's weighted average cost capital impairment longlived assets accordance sfas accounting impairment disposal longlived assets company periodically evaluates whether current facts circumstances indicate carrying value depreciable longlived assets held used may recoverable circumstances determined exist estimate undiscounted future cash flows produced longlived asset appropriate grouping assets compared carrying value determine whether impairment exists asset determined impaired loss measured based quoted market prices active markets available quoted market prices available estimate fair value based various valuation techniques including discounted value estimated future cash flows company reports asset disposed lower carrying value estimated net realizable value goodwill evaluated least annually impairment accordance sfas goodwill intangible assets sfas requires goodwill tested impairment using twostep process first step identify potential impairment second step measures amount impairment loss goodwill deemed impaired carrying amount reporting unit 's goodwill exceeds estimated fair value sfas requires indefinitelived intangible assets tested impairment using onestep process consists comparison fair value carrying value intangible asset intangible assets deemed impaired net book value exceeds estimated fair value estimates future cash flows based reasonable supportable assumptions projections require management 's judgment changes key assumptions company 's businesses prospects changes market conditions could result impairment charge equity investments company reviews equity investments impairment based determination whether decline market value investment company 's carrying value temporary making determination company considers accounting principles board opinion equity method accounting investments common stock sets forth factors evaluated determining whether loss value recognized including company 's ability hold investment market price market price fluctuations investment 's publicly traded shares inability investee sustain earnings capacity would justify carrying amount investment company 's investment imclone subject accounting see note alliances investments consolidated financial statements discussion company 's investment imclone retirement benefits company 's pension plans postretirement benefit plans accounted using actuarial valuations required sfas employers ' accounting pensions sfas employers ' accounting postretirement benefits pensions company considers accounting retirement plans critical management required make significant subjective judgments number actuarial assumptions including discount rates salary growth longterm return plan assets retirement turnover health care cost trend rates mortality rates depending assumptions estimates used pension postretirement benefit expense could vary within range outcomes material effect reported earnings addition assumptions materially affect accumulated benefit obligations future cash funding detailed discussion company 's retirement benefits see retirement benefits note retirement plans note postretirement benefit plans pensions consolidated financial statements restructuring downsize streamline operations rationalize manufacturing facilities company periodically recorded restructuring charges result company made estimates judgments regarding future plans including future termination benefits exit costs incurred restructuring actions take place actual results could vary estimates resulting adjustment earnings contingencies normal course business company subject contingencies legal proceedings claims arising business cover wide range matters including product liability environmental liability tax matters accordance sfas accounting contingencies company records accruals contingencies probable liability incurred amount loss reasonably estimated discussion contingencies reference made note income taxes note litigation matters consolidated financial statements income taxes december taxes provided approximately billion undistributed earnings foreign subsidiaries company invested expects invest undistributed earnings indefinitely future earnings repatriated united states company determines earnings remitted foreseeable future additional tax provisions would required due complexities tax laws assumptions would made practicable estimate amounts income taxes would provided company evaluates need deferred tax asset valuation allowance assessing whether likely realize deferred tax assets future assessment whether valuation allowance required often requires significant judgement including forecast future taxable income evaluation tax planning initiatives adjustments deferred tax valuation allowance made earnings period assessmentis made addition company operations tax jurisdictions located areas world subject audit jurisdictions tax audits nature often complex require several years resolve accruals tax contingencies require management make estimates judgments respect ultimate outcome tax audit actual results could vary estimates outlook company currently expects sales growth closely reflect underlying prescription trends sales growth expected benefit absence significant inventory workdown wholesalers consignment model expected sales growth drivers several key products including plavix avapro pravachol paraplatin abilify expected introduction atazanavir subject fda approval well growth otn business company also expects significant sales growth sustiva cardiolite products obtained october acquisition dupont pharmaceuticals partially offsetting growth drivers expected loss exclusivity several products including monopril serzone glucophage xr us taxol europe gross margins expected consistent gross margins adverse impact generic competition changes product mix expected offset growth new products continued growth current key products company plans increase product advertising promotion approximately midto high teens percentage basis focusing support abilify avapro plavix pravachol research development expenses expected comparable continued rebalancing drug discovery development provide additional support latestage development pipeline selling general administrative expenses expected increase single digits percentage basis underlying drivers operating expense growth include expected higher pension cost estimated negatively impact earnings minority interest income taxes approximately million lesser extent expected increase sales force expense due fullyear abilify sales force support fewer open sales force positions compared minority interest expense expected increase due higher sales products worldwide alliance sanofi company projects fully diluted earnings per share excluding impact inprocess research development may arise external development agreements noncomparable items company expects consignment model longer applied sales us pharmaceuticals wholesalers end except sales distribution agreement related otn thereafter company expects buying patterns fluctuations inventory levels wholesalers effect company 's financial results comparability prior periods actual results may differ materially estimates expectations described factors could affect estimates expectations described cautionary factors may affect future results cautionary factors may affect future results annual report including documents incorporated reference written oral statements company makes time time contain certain forwardlooking statements within meaning section securities act section e securities exchange act identify forwardlooking statements fact use words expect anticipate estimate may project guidance intend plan believe words terms similar meaning expression connection discussion future operating financial performance one also identify forwardlooking statements fact relate strictly historical current facts forwardlooking statements based current expectations involve inherent risks uncertainties including factors could delay divert change could cause actual outcomes differ materially current expectations statements likely relate among things company 's goals plans projections regarding company 's financial position results operations market position product development product approvals sales efforts expenses performance results current anticipated products outcome contingencies legal proceedings financial results based current expectations involve inherent risks uncertainties including factors could delay divert change next several years although possible predict identify factors may include following new government laws regulations health care reform initiatives united states state federal level countries ii changes fda foreign regulatory approval processes may cause delays approving preventing approval new products iii tax changes phasing tax benefits heretofore available united states certain foreign countries iv new laws regulations judicial decisions affecting pricing marketing competitive factors new products developed competitors lower prices superior performance features otherwise competitive company 's current products ii generic competition products mature patents expire products iii technological advances patents attained competitors iv problems licensors suppliers distributors v business combinations among company 's competitors major customers difficulties delays inherent product development manufacturing sale products may appear promising development may fail reach market numerous reasons including efficacy safety concerns inability obtain necessary regulatory approvals difficulty excessive cost manufacture ii seizure recall products iii failure obtain imposition limitations use loss patent intellectual property rights iv failure comply current good manufacturing practices application regulations quality assurance guidelines could lead temporary manufacturing shutdowns product shortages delays product manufacturing v manufacturing distribution problems legal difficulties preclude delay commercialization products adversely affect profitability including intellectual property disputes ii adverse decisions litigation including product liability commercial cases iii inability obtain adequate insurance withrespect type liability iv recalls pharmaceutical products forced closings manufacturing plants v government investigations vi claims asserting violations securities antitrust laws vii environmental matters viii tax liabilities increasing pricing pressures worldwide including rules practices managed care groups institutional governmental purchasers judicial decisions governmental laws regulations related medicare medicaid healthcare reform pharmaceutical reimbursement pricing general fluctuations buying patterns major distributors retail chains trade buyers may result seasonality pricing wholesaler buying decisions factors including effect incentives offered company 's wholesaler inventory management policies including workdown wholesaler inventory levels factors greater expected costs difficulties including unanticipated effects difficulties acquisitions dispositions events including obtaining regulatory approvals occurring connection evolving business strategies legal defense costs insurance expense settlement costs risk adverse decision related litigation changes advertising promotional spending categories spending may affect sales changes company 's structure resulting acquisitions divestitures mergers restructurings strategic initiatives economic factors company control changes business economic conditions including limited changes interest rates fluctuation foreign currency exchange rates changes business political economic conditions due recent terrorist attacks us threat future terrorist activity us parts world related us military action overseas changes accounting standards promulgated financial accounting standards board securities exchange commission american institute certified public accountants may require adjustments financial statements although company believes prudent plans assumptions assurance given goal plan set forth forwardlooking statements achieved readers cautioned place undue reliance statements speak date made company undertakes obligation release publicly revisions forwardlooking statements result new information future events otherwise item quantitative qualitative disclosures market risk company exposed market risk due changes currency exchange rates interest rates reduce risk company enters certain derivative financial instruments available costeffective basis hedge underlying economic exposure instruments also managed consolidated basis efficiently net exposures thus take advantage natural offsets derivative financial instruments used trading purposes gains losses hedging transactions offset gains losses underlying exposures hedged foreign exchange option contracts forward contracts used hedge anticipated transactions company 's primary foreign currency exposures relation us dollar euro canadian dollar japanese yen mexican peso table summarizes company 's outstanding foreign exchange contracts december fair value foreign exchange option contracts estimated using blackscholes model based yearend currency rates fair value option contracts forward contracts viewed relation fair value underlying hedged transactions overall reduction exposure adverse fluctuations foreign currency exchange rates weighted average fair strike price notional amount value maturity dollars million except currency rates foreign exchange forwards euro swedish krona swiss franc south african rand british pound total forwards foreign exchange options euro canadian dollar australian dollar total options total contracts december company held option contracts aggregate notional amount fair value million million respectively contracts primarily related right buy japanese yen right sell canadian australian dollars company also held foreign exchange forward contracts aggregate notional amount million fair value million contracts primarily related exposures euro mexican peso japanese yen british pound company uses derivative instruments part interest rate risk management policy derivative instruments used include interest rate swaps subject fairvalue hedge accounting treatment company executed five financial institutions several fixed floating interest rate swaps convert billion company 's fixed rate debt paid variable rate debt year ended december company recognized reduction interest expense million reflects benefit lower floating rate obtained swap agreement sfas requires revaluation fair value swap contracts well underlying debt hedged swap contracts underlying debt revalued resulting increase current assets longterm debt million swap contracts generally held maturity used trading speculative purposes following table summarizes interest rate swaps executed notional amount variable rate underlying debt received maturity fair value dollars millions interest rate contracts swaps associated notes due month us libor swaps associated notes due month us libor company also outstanding several interest rate foreign currency swaps related japanese yen notes due aggregate fair value instruments december million million respectively company million million longterm debt outstanding december respectively see note shortterm borrowings longterm debt note financial instruments consolidated financial statements additional information company maintains cash cash equivalents time deposits marketable securities various financial institutions order limit exposure one financial institution financial institutions located primarily us europe item financial statements supplementary data bristolmyers squibb company consolidated statement earnings millions except per share data year ended december earnings net sales cost products sold marketing selling administrative advertising product promotion research development acquired inprocess research development provision restructuring items litigation settlement charge gain sales businesses product lines asset impairment charge imclone interest expense expenseincome net earnings continuing operations minority interest income taxes provision income taxes minority interest net taxes earnings continuing operations discontinued operations net lossearnings net gain disposal net earnings earnings per common share basic earnings continuing operations discontinued operations net earnings net gain disposal net earnings diluted earnings continuing operations discontinued operations net earnings net gain disposal net earnings average common shares outstanding basic diluted dividends declared per common share includes minority interest expense net income loss unconsolidated affiliates accompanying notes integral part financial statements bristolmyers squibb company consolidated statement comprehensive income retained earnings dollars millions comprehensive income net earnings comprehensive income loss foreign currency translation net tax benefit taxes deferred gains losses derivatives qualifying hedges net taxes tax benefit minimum pension liability adjustment total comprehensive income loss comprehensive income retained earnings retained earnings january net earnings cash dividends declared zimmer common stock dividend retained earnings december accompanying notes integral part financial statements bristolmyers squibb company consolidated balance sheet dollars millions december assets current assets cash cash equivalents time deposits marketable securities receivables net allowances inventories including consignment inventory prepaid expenses total current assets property plant equipment net goodwill intangible assets net assets total assets liabilities current liabilities shortterm borrowings deferred revenue consigned inventory accounts payable dividends payable accrued litigation settlements accrued expenses accrued rebates returns us foreign income taxes payable total current liabilities liabilities longterm debt total liabilities commitments contingencies stockholders ' equity preferred stock convertible series authorized million shares issued outstanding liquidation value per share common stock par value per share authorized billion shares issued capital excess par value stock accumulated comprehensive loss retained earnings less cost treasury stock common shares total stockholders ' equity total liabilities stockholders ' equity accompanying notes integral part financial statements bristolmyers squibb company consolidated statement cash flows dollars millions year ended december cash flows operating activities net earnings depreciation amortization acquired inprocess research development litigation settlement charge asset impairment charge imclone provision restructuring items gain sales businessesproduct lines including discontinued operations operating items receivables inventories deferred revenue consigned inventory accounts payable accrued expenses income taxes product liability insurance recoverable pension contribution assets liabilities net cash provided operating activities cash flows investing activities proceeds sales time deposits marketable securities purchases time deposits marketable securities additions property plant equipment proceeds sales businessesproduct lines proceeds sale clairol purchase dupont dupont acquisition costs liabilities investment imclone business acquisitions including purchase trademarkspatents net net cash used provided investing activities cash flows financing activities shortterm borrowings longterm debt borrowings longterm debt repayments issuances common stock stock plans purchases treasury stock dividends paid net cash used provided financing activities effect exchange rates cash decrease increase cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year accompanying notes integral part financial statements bristolmyers squibb company notes consolidated financial statements note accounting policies basis consolidationthe consolidated financial statements include accounts bristolmyers squibb company controlled majority owned subsidiaries intercompany balances transactions eliminated use estimates preparation financial statements conformity gaap requires use estimates assumptions affect reported amounts assets liabilities disclosure contingent assets contingent liabilities date financial statements reported amounts revenues expenses reporting period significant assumptions employed estimates used determining values intangible assets restructuring charges accruals sales rebate return accruals legal contingencies tax assets tax liabilities well estimates used applying revenue recognition policy accounting retirement postretirement benefits including actuarial assumptions actual results could differ estimated results revenue recognition company recognizes revenue sales upon shipment product customers except case certain transactions us pharmaceuticals wholesalers accounted using consignment model gaap revenue recognized substantially risks rewards ownership transferred case sales made wholesalers result incentives excess wholesaler 's ordinary course business inventory level time understanding agreement course dealing consistent business practice company would extend incentives based levels excess inventory connection future purchases time incentives would cover substantially vary directly wholesaler 's cost carrying inventory excess wholesaler 's ordinary course business inventory level substantially risks rewards ownership transfer upon shipment accordingly sales accounted using consignment model determination sales wholesaler meet foregoing criteria involves evaluation variety factors number complex judgments consignment model company recognize revenue upon shipment product rather upon shipment product company invoices wholesaler records deferred revenue gross invoice sales price classifies inventory held wholesalers consignment inventory company 's cost inventory company recognizes revenue consignment inventory longer subject incentive arrangements later inventory sold wholesalers ' customers firstin firstout fifo basis company 's estimates inventory wholesalers deferred revenue consigned inventory based projected prescription demandbased sales products well company 's analysis thirdparty information including information obtained certain wholesalers respect inventory levels sellthrough customers thirdparty market research data company 's internal information company 's estimates subject inherent limitations estimates rely thirdparty data certain thirdparty information form estimates reflect limitations revenues reduced time sale reflect expected returns estimated based historical experience additionally provision made time sale discounts rebates estimated sales allowances based historical experience updated changes facts circumstances appropriate provision recorded reduction revenue company adopted emerging issues task force eitf january presents cost certain vendor considerations eg cooperative advertising payments shelving allowances manufacturers coupons reductions revenue instead advertising promotion expenses financial information prior periods presented reclassified comply income statement classification requirements new guidance million promotional expenses recorded reduction net sales certain promotional expenses reclassified primarily advertising promotion expenses reduction net sales amount million million respectively sales rebate return accruals medicaid managed healthcare sales rebate return accruals established period related revenue recognized resulting reduction sales establishment liability included accrued liabilities accrual recorded based estimate proportion recorded revenue result rebate return prime vendor chargebacks established similar manner recorded reduction accounts receivable million million december respectively income taxes provision income taxes determined using asset liability approach accounting income taxes approach deferred taxes represent future tax consequences expected occur reported amounts assets liabilities recovered paid provision income taxes represents income taxes paid payable current year plus change deferred taxes year deferred taxes result differences financial tax bases company 's assets liabilities adjusted changes tax rates tax laws changes enacted valuation allowances recorded reduce deferred tax assets likely tax benefit realized company record provision income taxes undistributed earnings foreign subsidiaries expect repatriate foreseeable future cash cash equivalents cash cash equivalents primarily include securities maturities three months less time purchase recorded cost approximates market value time deposits marketable securities time deposits marketable securities available sale recorded fair value approximates cost inventory valuation inventories generally stated average cost excess market capital assets depreciation expenditures additions renewals improvements capitalized cost depreciation generally computed straightline method based estimated useful lives related assets estimated useful lives major classes depreciable assets years buildings years machinery equipment fixtures company periodically evaluates whether current events circumstances indicate carrying value depreciable assets may recoverable impairment longlived assets effective january company adopted provisions sfas accounting impairment longlived assets adoption sfas material effect consolidated financial statements company sfas establishes accounting impairment longlived tangible intangible assets goodwill disposal segment business pursuant sfas company periodically evaluates whether current facts circumstances indicate carrying value depreciable assets held used may recoverable circumstances determined exist estimate undiscounted future cash flows produced longlived asset appropriate grouping assets compared carrying value determine whether impairment exists asset determined impaired loss measured based quoted market prices active markets available quoted market prices available estimate fair value based various valuation techniques including discounted value estimated future cash flows company reports asset disposed lower carrying value estimated net realizable value capitalized software certain costs obtain internal use software significant systems projects capitalized amortized estimated useful life software ranges four ten years costs obtain software projects significant expensed incurred capitalized software net accumulated amortization december million million respectively acquisitions company adopted sfas business combinations sfas requires companies use purchase method accounting business combinations initiated june investments company consolidates majority owned subsidiaries ability exercise control company accounts less owned companies ability exercise significant influence using equity method accounting company 's share net income losses equity investments included minority interest consolidated statement earnings company periodically reviews equity investments impairment adjusts investments fair value decline market value deemed temporary company recorded asset impairment charge million temporary decline market value imclone systems incorporated imclone longterm investments securities comprises marketable equity securities securities investments market values readily available included assets marketable equity securities classified availableforsale reported fair value fair value based quoted market prices end reporting period securities investments market values readily available carried cost unrealized gains losses reported net related tax effects component accumulated comprehensive income loss stockholders ' equity sold time sale gains losses calculated specific identification method recognized incomeexpense losses also recognized income decline market value deemed temporary goodwill company adopted sfas goodwill intangible assets january certain provisions adopted july respect amortization goodwill arising acquisitions made june sfas addresses initial recognition measurement intangible assets acquired outside business combination recognition measurement goodwill intangible assets subsequent acquisition new rules goodwill longer amortized subject annual impairment tests connection accounting change goodwill resulting company 's acquisition dupont pharmaceuticals business investment imclone amortized goodwill arising business acquisitions prior july amortized straightline basis periods ranging years goodwill amortized effective january goodwill amortization expense million accordance sfas goodwill tested impairment upon adoption new standard annually thereafter sfas requires goodwill tested impairment using twostep process first step identify potential impairment second step measures amount impairment loss goodwill deemed impaired carrying amount reporting unit 's goodwill exceeds estimated fair value company completed goodwill impairment assessment indicated impairment goodwill intangible assets intangible assets consisting patents technology licenses amortized straightline basis periods ranging years representing remaining life assets sfas requires indefinitelived intangible assets tested impairment using onestep process consists comparison fair value carrying value intangible asset intangible assets deemed impaired net book value exceeds estimated fair value intangible assets evaluated impairment accordance sfas described product liability accruals product liability recorded undiscounted basis probable liability incurred amount liability reasonably estimated based existing information accruals adjusted periodically assessment efforts progress additional information becomes available receivables related insurance thirdparty recoveries product liabilities recorded undiscounted basis probable recovery realized insurance recoverable recorded balance sheet general payment terms two years less amounts receivables recognized excess related liabilities december million million respectively contingencies normal course business company subject contingencies legal proceedings claims arising business cover wide range matters including among others product liability environmental liability tax matters accordance sfas accounting contingencies company records accruals contingencies probable liability incurred amount loss reasonably estimated discussion contingencies reference made note income taxes note litigation matters consolidated financial statements derivative financial instruments derivative financial instruments used company principally management interest rate foreign currency exposures company hold issue derivative financial instruments trading purposes company records derivative instruments balance sheet fair value changes derivative 's fair value recognized earnings unless specific hedge criteria met derivative designated fair value hedge changes fair value derivative hedged item attributable hedged risk recognized charge credit earnings derivative designated cash flow hedge effective portions changes fair value derivative recorded comprehensive income loss recognized consolidated statement earnings hedged item affects earnings cash flows classified consistent underlying hedged item purchased foreign currency options entire change fair value included measurement hedge effectiveness cash flow hedges ineffective portions changes fair value cash flow hedges recognized charge credit earnings company designates assigns derivatives hedges forecasted transactions specific assets specific liabilities hedged assets liabilities sold extinguished forecasted transactions hedged longer expected occur company recognizes gain loss designated hedging financial instruments shipping handling costs company typically charge customers shipping handling costs shipping handling costs included marketing selling administrative expenses million million million respectively advertising costs advertising costs expensed incurred advertising expense million million million respectively acquired inprocess research development fair value inprocess research development acquired business combination determined independent appraisal based present value research project 's projected cash flows utilizing income approach consistent aicpa practice aid assets acquired business combinations used research development activities focus software electronic devices pharmaceutical industries future cash flows predominately based net income forecast project consistent historical pricing margins expense levels similar products revenues estimated based relevant market size growth factors expected industry trends individual project life cycles life research project 's underlying patent determining fair value research project expected revenues first adjusted technical risk completion resulting cash flows discounted rate approximating company 's weighted average cost capital acquired inprocess research development expensed incurred underlying product received regulatory approval future alternative use addition costs nonrefundable related acquisition licensing products yet received regulatory approval marketed alternative future use charged earnings incurred earnings per share basic earnings per common share computed using weightedaverage number shares outstanding year diluted earnings per common share computed using weightedaverage number shares outstanding year plus incremental shares outstanding assuming exercise dilutive stock options stock compensation plans company applies accounting principles board apb opinion accounting stock issued employees related interpretations accounting stockbased compensation plans company recognize compensation expense stock options granted plans exercise price option date grant equal fair market value date grants restricted stock company recognizes compensation expense straightline basis period restrictions expire following table summarizes company 's results pro forma basis recorded compensation expense based upon fair value grant date awards plans consistent methodology prescribed sfas accounting stockbased compensation dollars millions except per share data net earnings reported pro forma basic earnings per share reported pro forma diluted earnings per share reported pro forma see note stockholders ' equity consolidated financial statements additional information december fasb issued sfas accounting stockbased compensationtransition disclosure sfas amends sfas accounting stockbased compensation provide alternative methods transition voluntary change fair value based method accounting stockbased employee compensation addition sfas amends disclosure requirements sfas require prominent disclosures annual interim financial statements method accounting stockbased employee compensation effect methodused reported results provisions sfas effective financial statements year ended december sfas material impact company 's consolidated financial statements adoption standard require company change company plan change fair value based method accounting stockbased compensation reclassifications certain prior year amounts reclassified conform current year presentation accounting policies implemented variable interest entities january fasb issued interpretation consolidation variable interest entities fin fin requires variable interest entity consolidated company company subject majority risk loss variable interest entity 's activities entitled receive majority entity 's residual returns fin also requires disclosures variable interest entities company required consolidate significant variable interest consolidation requirements fin apply immediately variable interest entities created january existing entities first fiscal year interim period beginning june certain disclosure requirements apply financial statements issued january regardless variable interest entity established company process assessing impact pronouncement consolidated financial statements based preliminary analysis impact fin company believes reasonably possible imclone could meet criteria considered variable interest entity relation company accordingly company included required transitional disclosures fin note alliances investments consolidated financial statements guarantees november fasb issued interpretation guarantor 's accounting disclosure requirements guarantees including indirect guarantees indebtedness others fin fin requires guarantor recognize liability inception guarantee fair value obligation undertaken issuing guarantee include detailed disclosure respect guarantees types contracts company enters meet scope interpretation financial performance standby letters credit behalf whollyowned subsidiaries fin effective guarantees issued modified december initial adoption accounting pronouncement expected material effect company 's consolidated financial statements note alliances investments sanofisynthelabo company entered codevelopment comarketing agreement sanofisynthelabo sanofi two products avaproavalide irbesartan angiotensin ii receptor antagonist indicated treatment hypertension plavix clopidogrel platelet inhibitor worldwide alliance operates framework two geographic territories one americas australia europe asia two territory partnerships formed manage central expenses marketing research development royalties supply finished product individual countries country level agreements either copromote whereby partnership formed parties sell brand comarket whereby parties operate sell brands independently place company acts operating partner territory covering americas principally us canada puerto rico latin american countries australia owns majority controlling interest territory company consolidates country partnership results territory records sanofi 's share results minority interest expense net taxes million million million company recorded sales territory comarketing countries million million million sanofi acts operating partner territory covering europe asia owns majority controlling interest territory company accounts investment partnership entities territory equity method records share results net income unconsolidated affiliates included minority interest net taxes company 's share net income partnership entities million million million fourth quarter company sanofi modified codevelopment arrangement irbesartan form alliance part company contributed irbesartan intellectual property sanofi agreed pay company million million fourth quarters respectively company accounts transaction sale interest license defers amortizes million income expected useful life license approximately eleven years company amortized income million million respectively otsuka company entered worldwide commercialization agreement otsuka pharmaceutical co ltd otsuka codevelop copromote abilify aripiprazole treatment schizophrenia total milestone payments made otsuka december million million expensed acquired inprocess research development remaining million capitalized million refundable abilify granted approval us food drug administration fda million paid upon fda approval product november million capitalized payments amortized remaining patent life product approximately years company began copromoting product otsuka us puerto rico november revenue earned otsuka ships product title passes customer company records alliance revenue share net sales copromotion countries records expenses related product introductory sales copromotion countries million imclone november company purchased million shares imclone per share million represented approximately imclone shares outstanding prior company 's commencement public tender offer imclone shares transaction accounted using equity method accounting imclone biopharmaceutical company focused developing targeted cancer treatments include growth factor blockers cancer vaccines antiangiogenesis therapeutics equity investment imclone part strategic agreement company imclone also included arrangement codevelop copromote investigational cancer drug erbitux series payments originally totaling billion companypaid imclone milestone payment million march agreement imclone revised reduce total payments million billion revised agreement company paid imclone million march million march pay aggregate million upon achievement two milestones million paid imclone march million expensed inprocess research development first quarter remaining million recorded additional equity investment eliminate income statement effect portion milestone payment company economic claim ownership interest imclone also revised agreement company pay imclone distribution fee based flat rate product revenues north america terms revised agreement continue fourth quarter company recorded pretax charge approximately million comprised million writeoff acquired process research development related equity investment million writeoff portion million milestone payment made remaining million million milestone payment recorded additional equity investment eliminate income statement effect portion milestone payment company economic claim ownership interest imclone acquired inprocess research development charge related three oncology research projects phase later stage development one research project erbitux late phase iii development amount determined identifying research projects areas technological feasibility established alternative future use projected fda approval dates used years time company expected projects begin generate cash flows cost complete projects estimated million research development projects considered valuation subject normal risks uncertainties associated demonstrating safety efficacy required obtain fda approval purchase price allocation resulted million patent technology intangible assets amortized weightedaverage useful lives years approximately million goodwill amortized december imclone announced fda refused accept filing biologics license application bla submitted imclone erbitux bla submitted gain marketing approval treat irinotecanrefractory colorectal carcinoma january subcommittee oversight investigations house energy commerce committee announced investigating questions conduct imclone development erbitux january imclone announced received informal inquiry securities exchange commission well inquiries department justice aforementioned subcommittee company cooperating investigations million paid equity investment million milestone payment million million expensed acquired process research development remaining million recorded equity investment additional million recorded investment primarily acquisition costs resulting carrying value million december third quarter company recorded pre tax charge earnings million temporary decline market value imclone based decline value imclone 's shares fair value equity investment imclone used record impairment determined based market value imclone shares september total equity investment imclone december million per share basis carrying value imclone investment closing market price imclone shares december respectively compared respectively december closing market price imclone shares february per share company recorded million net loss share imclone 's losses company process assessing impact fin consolidation variable interest entities could consolidated financial statements based preliminary assessment impact fin company believes reasonably possible imclone could considered variable interest entity relation company september imclone total assets million total stockholders ' deficit million accumulated deficit million nine months ended september imclone million net loss summary financial information following presents summarized financial information company 's equity investments imclone sanofi europe asia dollars millions revenues gross profit net income current assets noncurrent assets current liabilities noncurrent liabilities summarized financial information includes imclone data date investment november imclone public company yet filed sec audited financial statements otherwise made public disclosure audited financial results year ended december summarized financial information respect imclone based estimated preliminary unaudited financial information provided company imclone company recorded share imclone 's losses based preliminary unaudited information year ended december although company believes preliminary unaudited information reliable imclone 's financial information responsibility imclone 's management event imclone 's reported financial information year ended december differs significantly preliminary unaudited information company record adjustment equity earnings disclose impact difference results provide revised summarized financial information quarterly report form q quarterly period ended march public filings note restructuring items activities company recorded pretax restructuring charges million relating reduction elimination nonstrategic research efforts well consolidation research facilities workforce reductions downsizing streamlining worldwide operations charge million relates employee termination benefits approximately employees including research manufacturing administrative personnel remaining million million represents asset write downs exit costs closure facilities related expenses million impairment charge company 's investment deltagen addition million accelerated depreciation relating planned shutdown research facilities us included research development expense million inventory writeoffs associated projects included cost products sold charges offset adjustment prior period restructuring reserves million million due lower expected separation costs million due higher anticipated proceeds disposal assets previously written restructuring million projects cancelled addition million adjustment cost products sold made reflect reversal inventory reserves associated cancelled projects company expects substantially complete restructuring activities late following table presents detail charges operating segment type company allocate restructuring charges business segments employee employee termination asset write exit terminations benefits downs costs total dollars millions pharmaceuticals nutritionals healthcare corporateother subtotal reduction reserves changes estimates restructuring reflected consolidated statement earnings activities company recorded pretax restructuring charges million restructuring programs included termination benefits asset writedowns costs implemented downsize streamline operations rationalize manufacturing facilities terminate certain sales force research contract obligations time recorded actions expected completed within twelve months expected substantially complete early additional costs associated restructuring projects include million sales deductions customer charge backs relating abandonment nonstrategic pharmaceutical product lines included reduction sales million related inventory writeoffs included cost products sold restructuring charges offset reversal million result change estimate relating separation costs cancellation projects previously provided charge consisted million employee termination benefits employees severance actions result companywide restructuring effort downsize streamline operations impacted virtually areas including sales force manufacturing administrative research personnel addition million accrued termination contract sales force million accrued exit costs primarily related costs associated closure certain manufacturing operations charge also included million fixed asset writedowns million asset writedowns primarily related exit nutritionals business eastern europe closure pharmaceutical production facility us closure research facility france following table presents detail charges operating segment type company allocate restructuring charges business segments employee asset employee termination write exit terminations benefits downs costs items total dollars millions pharmaceuticals nutritionals healthcare corporateother subtotal reduction reserves changes estimates restructuring reflected consolidated statement earnings items recorded include pretax charge million contribution bms foundation million establish additional reserves future breast implant claims million costs associated product recall activities company recorded pretax restructuring charges million restructuring programs included termination benefits asset writedowns costs implemented consolidate us sales force rationalize manufacturing facilities downsize streamline operations additional costs associated restructuring projects year include million related inventory writeoffs included cost products sold actions substantially complete charge consisted million employee termination benefits approximately employees severance actions focused sales force manufacturing administrative personnel addition million costs recorded consisting mainly certain contract termination facility remediation expenses charge also included million asset writedowns primarily related exit research facility japan manufacturing operations us certain international operations convatec addition assets million written consisted primarily capitalized software longer used result sales force actions described following table presents detail charges operating segment type company allocate restructuring charges business segments employee asset employee termination write exit terminations benefits downs costs items total dollars millions pharmaceuticals nutritionals healthcare corporateother totals items recorded include pretax charge million contribution bms foundation million costs associated product recall restructuring charges spending liabilities associated prior current actions follows employee termination exit cost liability liability total dollars millions balance december charges spending changes estimate balance december charges spending changes estimate balance december charges spending changes estimate balance december liabilities reflected accrued expenses consolidated balance sheet note acquisitions divestitures dupont pharmaceuticals acquisitionon october company acquired dupont pharmaceuticals business dupont e du pont de nemours company billion cash results dupont included consolidated financial statements date acquisition dupont primarily domestic pharmaceutical imaging product business focused research development acquisition financed proceeds issuance billion commercial paper issuance billion mediumterm notes internal cash flows following summary final allocation estimated fair values assets acquired liabilities assumed dollars millions current assets property plant equipment intangible assets acquired inprocess research development goodwill assets total assets acquired current liabilities restructuring liabilities acquisition liabilities long term liabilities total liabilities assumed purchase price total intangible assets million amortized weightedaverage useful lives include core developed technology million years weightedaverage useful life respectively patents million year weightedaverage useful life goodwill million assigned pharmaceuticals segment total amount million expected deductible tax purposes year period time acquisition billion purchase price allocated acquired inprocess research development charged earnings fourth quarter charge associated five research projects cardiovascular central nervous system oncology antiinfective therapeutic areas ranging preclinical phase ii development stage amount determined identifying research projects technological feasibility established alternative future use projected fda approval dates years time company expected projects begin generate cash flows cost complete research projects estimated billion research development projects considered valuation subject normal risks uncertainties associated demonstrating safety efficacy required obtain fda approval company terminated one projects antiinfective therapeutic area termination project expected material impact company 's future earnings cash flow remaining four projects currently proceeding consistent original assumptions used valuation research development projects considered valuation subject normal risks uncertainties associated demonstrating safety efficiency required fda approval connection acquisition company recorded million restructuring liabilities result severance relocation workforce elimination duplicate facilities contract terminations costs recognized company liability assumed acquisition date resulting additional goodwill liabilities consisted million employee termination benefits approximately employees million related closure facilities million contract terminations million originally recorded accrued expenses reduced million december million december reduction balance due cash payments million adjustment reverse previously recorded liabilities million corresponding reduction goodwill adjustment primarily due lower expected separation costs contract termination expenses facilities exit costs related acquisition following unaudited pro forma financial information presents results acquisition occurred beginning respective periods year ended december dollars millions except per share data net sales net earnings earnings per sharebasic earnings per sharediluted unaudited pro forma results prepared comparative purposes include certain adjustments additional amortization expense result identifiable intangible assets arising acquisition increased interest expense acquisition debt exclude acquired inprocess research development charge related dupont acquisition pro forma net earnings earnings per share amounts include billion gain sale clairol pro forma results necessarily indicative either results operations actually would resulted acquisition effect beginning respective periods future results company completed sale two branded products moisturel duricef resulted pretax gain millionin company completed sale three pharmaceutical products corzide delestrogen florinef licensing rights corgard us estrace tablets apothecon commodity business solage viactiv product lines resulted pretax gain million company completed sale three pharmaceutical products estrace cream ovcon ovcon well sea breeze brand japan resulting pretax gain million note discontinued operations company completed sale clairol procter gamble cash proceeds approximately billion sale resulted pretax gain billion billion taxes included gain disposal discontinued operations addition company spun zimmer holdings inc taxfree distribution resulting common stock dividend million company resolved several postclosing matters associated previously discontinued businesses resulting increase million gain disposal company recorded million credit retained earnings related adjustment zimmer pension liability affecting spinoff zimmer company completed sale matrix cosmair inc wholly owned us subsidiary l'oreal sa resulting pretax gain million million taxes gain included gain disposal discontinued operations net sales earnings discontinued operations follows dollars millions net sales earnings income taxes income taxes net earnings discontinued operations earnings income taxes include restructuring charges million net loss million reflected statement earnings reflects settlement litigation related business included discontinued operations consolidated statement cash flows includes clairol zimmer businesses date disposition net assets discontinued operations december million consisting current assets million longterm assets million less liabilities principally current million company uses centralized approach cash management financing operations accordingly company allocate debt businesses cash flows operating investing activities principally investing discontinued operations years ended december million billion including approximately billion proceeds sale clairol million including million proceeds sale matrix respectively note earnings per share computations basic earnings per common share diluted earnings per common share follows year ended december millions except per share amounts earnings continuing operations discontinued operations net lossearnings net gain disposal net earnings basic average common shares outstanding earnings continuing operations discontinued operations net earnings net gain disposal net earnings diluted average common shares outstanding incremental shares outstanding assuming exercise dilutive stock options earnings continuing operations discontinued operations net earnings net gain disposal net earnings weightedaverage shares issuable upon exercise stock options included diluted earnings per share calculation dilutive million million million note incomeexpense components incomeexpense year ended december dollars millions interest income foreign exchange transaction lossgain net income expense net note income taxes components earnings loss continuing operations minority interest income taxes year ended december dollars millions us nonus amounts categorized based location taxing authorities provision income taxes attributable continuing operations consisted year ended december dollars millions currentus nonus deferred us nonus company 's provision income taxes different amount computed applying statutory us federal income tax rate earnings continuing operations minority interest income taxes result following earnings minority interest income taxes dollars millions earnings continuing operations minority interest income taxes us statutory rate effect operations ireland puerto rico switzerland state local taxes increase valuation allowance changes estimate contingent tax matters foreignother effective tax rate continuing operations increased due primarily decrease effective tax rate benefit operations ireland puerto rico switzerland reflecting lesser percentage total pretax income generated jurisdictions well current year us tax cost associated dividend switzerland prepaid taxes december million million respectively deferred income taxes included assets december million million respectively components prepaid deferred income taxes consisted december dollars millions acquired inprocess research development consignment inventory items foreign tax credit carryforward legal settlement restructuring acquisition divestiture reserves state tax net operating loss carryforward sales returns allowances research experimentation tax credit carryforward postretirement pension benefits depreciation net valuation allowance decrease net prepaid deferred tax assets december december relates primarily consignment andother inventory items well restructuring acquisition divestiture reserve reductions valuation allowance million december relates million state net deferred tax assets million state net operating loss carryforwards million foreign tax credit carryforwards company currently believe likely realized future income taxes paid year million million million respectively current tax benefit realized upon exercise stock options charged capital excess par amounted million million million respectively company settled us federal income tax returns internal revenue service us federal income taxes provided substantially unremitted earnings nonus subsidiaries since management 's practice intent indefinitely postpone remittance total amount net unremitted earnings nonus subsidiaries approximately billion december certain tax contingencies exist probable reasonably estimable amounts recognized december certain tax contingencies either considered probable reasonably estimable company time although company reasonably estimate possible amount contingency possible contingencies could material effect changes estimates related contingent tax matters included rate reconciliation year ended december company recognized income tax benefit million due settlement certain prior year tax matters determination company expected settlement ongoing tax litigation also company reorganized structure ownership many nonus subsidiaries principal purpose reorganization facilitate company 's ability efficiently deploy financial resources outside us company believes reorganization transactions generally taxfree inside outside us possible however taxing authorities particular jurisdictions could assert tax liabilities arising reorganization transactions operations reorganized subsidiaries reasonably possible predict whether taxing authority assert tax liability reasonably estimate possible loss range loss respect asserted tax liability company would vigorously challenge assertion believes would prevail assurance result company prevail final nonappealable determinations possible impact could material note accounts receivable december dollars millions accounts receivabletrade accounts receivablemiscellaneous less allowances receivables receivables net reflects allowances bad debts note inventories major categories inventory follow december dollars millions finished goods work process raw packaging materials consignment inventory note consignment significant portion company 's us pharmaceuticals sales made wholesalers company experienced substantial buildup wholesalerinventories us pharmaceuticals business several years primarily buildup primarily due sales incentives offered company wholesalers company accounts certain sales pharmaceutical products cardinal health inc cardinal mckesson corporation mckesson using consignment model based part relationship amount incentives offered wholesales amount inventory held wholesalers company determined shipments product cardinal shipments product mckesson met consignment model criteria set forth revenue recognition note accounting policies consolidated financial statements july july respectively case continuing end period thereafter accordingly consignment model required applied shipments prior respective periods company recognized revenue respect sales cardinal mckesson upon shipment product although company generally views approximately one month supply desirable level wholesaler inventory goingforward basis level wholesaler inventory representative industry average applying consignment model sales cardinal mckesson company defined inventory excess wholesaler 's ordinary course business inventory level inventory two weeks three weeks supply respectively based levels inventory cardinal mckesson required used basis negotiation incentives granted march company entered distribution agreement mckesson provision warehousing order fulfillment services company 's oncology therapeutics network otn specialty distributor anticancer medicines related products terms agreement mckesson purchases oncology products service otn 's fulfillment needs number vendors including company subsequent shipment product mckesson company significant continuing involvement transaction including marketing product enduser invoicing customer collecting receivables customer behalf mckesson addition otn keeps credit risk responsible shipping costs customer company accounts sales using consignment model defers recognition revenue products sold mckesson transactions resulted deferred revenue million million december respectively company recognized approximately million previously recorded deferred revenue net sales company projects approximately million deferred revenue recognized net sales significant portion expected recognized first quarter note property plant equipment major categories property plant equipment follow december dollars millions land buildings machinery equipment fixtures construction progress less accumulated depreciation capitalized interest included categories property plant equipment shown company capitalized million interest years ended december note goodwill changes carrying amount goodwill years ended december follows pharmaceuticals nutritionals healthcare segment segment segment total dollars millions balance december amortization expense additions balance december purchase accounting adjustments relate recent acquisitions change exit cost estimate purchase price allocation adjustments balance december excludes million goodwill related discontinued operations note intangible assets intangible assets major asset class follows december dollars millions patentstrademarks licenses technology less accumulated amortization net carrying amount amortization expense intangible assets majority included costs products sold years ended december million million million respectively expected amortization expense next five years related current balance intangible assets follows years ending december dollars millions note shortterm borrowings longterm debt included shortterm borrowings amounts due foreign banks million million current installments longterm debt million million december respectively us commercial paper outstanding december million average interest rate commercial paper outstanding december proceeds commercial paper issuances used general corporate purposes average interest rate shortterm borrowings current installments longterm debt december respectively company consolidated two credit facilities aggregating million syndicate lenders support commercial paper program credit facility consists million fiveyear revolving credit facility extendable anniversary date consent lenders borrowings outstanding credit facility december company unused shortterm lines credit foreign banks million december components longterm debt december dollars millions notes due notes due debentures due debentures due debentures due yen notes due euro interest yen principal term loan due industrial revenue bonds due variable rate industrial revenue bonds due various rate yen term loans due yen notes due capitalized leases company issued billion debt notes billion matures remaining billion matures company option redeem time portion notes redemption price equal sum principal amount notes redeemed plus accrued interest redemption date premium face value paid redeem notes effective interest rates series notes respectively effective interest rates issuances approximated stated interest rate company entered fixed floating interest rate swaps billion longterm debt cash payments interest million million million respectively payments due period total dollars millions longterm debt payments included shortterm borrowings company 's consolidated balance sheet result previously disclosed restatement previously issued financial statements company delayed filing quarterly report form q quarterly period ended september third quarter form q previously disclosed delay resulted breach company delivery sec filing obligations indenture indenture company jpmorgan chase bank formerly chase manhattan bank company approximately billion longterm debt outstanding certain credit agreements gave certain rights trustee indenture respective lenders credit agreements accelerate maturity company 's indebtedness neither trustee respective lenders exercised right accelerate company filed third quarter form q sec cured noncompliance abovementioned obligations indenture credit agreements accordingly debt outstanding indenture credit agreements longer accelerated therefore classified longterm debt company 's consolidated balance sheet december company provided financial guarantees form standby letters credit performance bonds majority standby letters credit us nuclear regulatory commission massachusetts department public health relating company 's medical imaging manufacturing operations insurance companies support third party liability programs performance bonds relate sale company product various foreign ministries health middle east company believes significant majority guarantees expire without funded amounts obligations presented following table expiration period less total year years expiry dollars millions standby letters credit performance bonds guarantees total commercial commitments note stockholders ' equity changes capital shares treasury stock capital excess par value stock common stock treasury capital excess common stock shares cost treasury par value issued shares stock stock dollars millions balance december issued pursuant stock plans options conversions preferred stock purchases balance december issued pursuant stock plans options conversions preferred stock purchases balance december issued pursuant stock plans options conversions preferred stock purchases balance december share company 's preferred stock convertible shares common stock callable company 's option reductions number issued shares preferred stock due conversions shares common stock dividends declared per common share accumulated balances related component comprehensive income loss follows foreign currency deferred loss minimum pension accumulated translation effective hedges liability adjustment comprehensive loss dollars millions balance december adoption sfas comprehensive income loss balance december comprehensive income loss balance december company expects recognize million deferred hedging gains earnings next twelve months stock compensation plans company 's stock incentive plan officers directors key employees may granted options purchase company 's common stock less market price date option granted options generally become exercisable installments per year first fourth anniversaries grant date maximum term years additionally plan provides granting stock appreciation rights whereby grantee may surrender exercisable rights receive common stock andor cash measured excess market price common stock option exercise price plan also provides granting performancebased stock options certain key executives terms stock incentive plan authorized shares include outstanding shares per year well number shares tendered prior year pay purchase price options number shares previously utilized satisfy withholding tax obligations upon exercise shares available grant prior year granted year shares cancelled forfeited expired also available future grant plan incorporates company 's longterm performance awards addition stock incentive plan provides granting shares common stock key employees subject restrictions continuous employment restrictions generally expire fiveyear period date grant compensation expense recognized restricted period december restricted shares outstanding plan respectively teamshare stock option plan fulltime employees excluding key executives granted options purchase company 's common stock market price date options granted company authorized shares issuance plan individual grants generally become exercisable evenly third fourth fifth anniversary grant date maximum term years december shares exercised plan fair value options granted estimated per common share per common share per common share respectively date grant using blackscholes optionpricing model following assumptions dividend yield volatility riskfree interest rate assumed forfeiture rate expected life years stock option transactions shares common stock weighted average exercise price available shares option plans plan plan balance december authorized granted exercised lapsed balance december authorized granted granted result zimmer spinoff exercised lapsed balance december authorized granted exercised lapsed balance december effective spinoff zimmer august unexercised bristolmyers squibb stock options held zimmer employees converted zimmer stock options remaining unexercised bristolmyers squibb stock options number stock options exercise price adjusted preserve intrinsic value stock options ratio exercise price fair value existed prior spinoff following tables summarize information concerning company 's stock compensation plans currently outstanding exercisable options number securities remaining available future issuance number securities weighted average exercise equity compensation issued upon exercise price outstanding plans excluding outstanding options options warrants securities reflected warrants rights rights column plan category b c equity compensation plans approved security holders equity compensation plans approved security holders options outstanding options exercisable range weighted average weighted average number weighted average exercise prices number outstanding remaining contractual life exercise price exercisable exercise price december shares common stock reserved issuance pursuant stock plans options conversions preferred stock options related discontinued operations included amounts material note financial instruments company exposed market risk due changes currency exchange rates interest rates result company utilizes foreign exchange option forward contracts offset effect exchange rate fluctuations anticipated foreign currency transactions primarily intercompany inventory purchases expected occur within next year company exposures net foreign currency denominated assets liabilities approximated million million december respectively primarily europe japan mexico canada company mitigates effect exposures thirdparty borrowings exposures net foreign currency denominated assets liabilities related discontinued operations included amounts material foreign exchange option contracts forward contracts used hedge anticipated transactions company 's primary foreign currency exposures relation us dollar euro canadian dollar japanese yen mexican peso notional amounts company 's foreign exchange derivative contracts december million million respectively derivatives qualify hedges future cash flows effective portion changes fair value temporarily recorded comprehensive income recognized earnings hedged item affects earnings ineffective portion hedges reported earnings occurs notional amounts foreign exchange derivative contracts related discontinued operations included amounts material fair value option forward contracts recorded prepaid expenses december million million respectively fair values company 's derivative instruments based relevant market information including current forward currency exchange rates current interest rates fair value option contracts estimated using blackscholes model based yearend currency rates fair value foreign exchange forward contracts based yearend forward currency rates company uses derivative instruments part interest rate risk management policy derivative instruments used include fixed floating rate interest rate swaps subject fairvalue hedge accounting treatment company entered several fixed floating interest rate swapcontracts five financial institutions notional amount transactions billion period ended december accordance sfas company recognized reduction interest expense million reflects benefit lower floating rate obtained swap compared fixed rate underlying debt swap contracts well underlying debt hedged recorded fair value resulted increase current assets longterm debt million swap contracts generally held maturity company use derivative financial instruments trading speculative purposes company entered interest rate hedge contracts notional amount billion manage exposure changes interest rates longterm fixedrate debt issues connection dupont imclone transactions see note alliances investments note acquisitions divestitures consolidated financial statements contracts designated hedges variability cash flows due changes long term benchmark interest rates also company settled existing interest rate hedge contracts recorded contract settlements fair value resulting million deferred loss net taxes accumulated comprehensive loss recognized yield adjustment terms related borrowings carrying amount company 's financial instruments include cash equivalents marketable securities accounts receivable accounts payable approximates fair value december longterm debt noted difference fair value carrying value material note segment information effective first quarter company reorganized three groups support pharmaceutical company related healthcare businesses result reorganization three reportable segmentspharmaceuticals nutritionals healthcare pharmaceuticals segment comprised global pharmaceutical international excluding japan consumer medicines businesses nutritionals segment consists mead johnson nutritionals primarily infant formula business healthcare segment consists convatec medical imaging consumer medicines us japan businesses company 's products sold principally wholesale retail trade nationally internationally certain products also sold drug manufacturers hospitals medical profession three wholesalers accounted approximately company 's net sales two wholesalers accounted respectively company 's net sales sales concentrated pharmaceuticals segment sales selected products product categories follows dollars millions pharmaceuticals pravachol oncology therapeutics network plavix taxol paraplatin avapro sustiva zerit monopril coumadin glucophage xr videxvidex ec glucovance serzone glucophage ir nutritionals infant formulas healthcare ostomy cardiolite wound care business segments earnings minority interest net sales income taxes yearend assets dollars millions pharmaceuticals nutritionals healthcare total segments corporateother total included earnings minority interest income taxes operating segments cost capital charge elimination cost capital charge included corporateother addition corporateother principally consists interest income interest expense certain administrative expenses allocations business segments certain corporate programs corporateother also includes gain sales businessesproduct lines million million million respectively provision restructuring items million million million respectively litigation settlement provision million million respectively pharmaceuticals segment includes charge acquired inprocess research development million million million respectively addition pharmaceuticals includes million deductions customer chargebacks related abandoned product lines included reduction net sales corporateother assets consist cash cash equivalents time deposits marketable securities goodwill certain assets capital expenditures depreciation dollars millions pharmaceuticals nutritionals healthcare total segments corporateother total capital expenditures depreciation expense consolidated statement cash flows includes capital expenditures related discontinued operations million million respectively million million depreciation expense related discontinued operations respectively geographic areas net sales yearend assets dollars millions united states europe mideast africa western hemisphere pacific total note leases minimum rental commitments noncancelable operating leases primarily real estate effect december years ending december dollars millions later years total minimum payments less total minimum sublease rentals net minimum rental commitments operating lease rental expense net sublease rental income million million million million million note retirement plans company certain subsidiaries defined benefit pension plans defined contribution plans regular fulltime employees principal pension plan bristolmyers squibb retirement income plan funding policy contribute amounts provide current service fund past service liability plan benefits based primarily years credited service participant 's compensation plan assets consist principally equity fixed income securities company domestic curtailmentsettlement loss approximately million resulting reductions employment levels primarily connection restructuring activities clairol divestiture cost company 's defined benefit plans included following components dollars millions service cost benefits earned year interest cost projected benefit obligation expected earnings plan assets net amortization deferral net pension expense curtailments settlements total pension expense weightedaverage actuarial assumptions company 's pension plans follows december discount rate compensation increase longterm rate return plan assets changes projected benefit obligation plan assets december dollars millions benefit obligation beginning year service costbenefits earned year interest cost projected benefit obligation curtailments settlements transfer dupont actuarial losses benefits paid benefit obligation end year fair value plan assets beginning year actual earnings losses plan assets employer contribution settlements transfer dupont benefits paid fair value plan assets end year plan assets excess less projected benefit obligation unamortized net obligation adoption unrecognized prior service cost unrecognized net gains losses net amount recognized amounts recognized consolidated balance sheet consist ofprepaid benefit cost accrued benefit liability asset comprehensive income net amount recognized projected benefit obligation accumulated benefit obligation fair value plan assets pension plans accumulated benefit obligations excess plan assets million million million respectively december million million million respectively december million million million respectively december attributable primarily us unfunded benefit equalization plan several plans international markets december dupont pharmaceuticals company us pension plan december unrecognized net actuarial loss determined based market related value plan assets million amount exceeded greater projected benefit obligation market related value plan assets million unless offset future unrecognized gains higher discount rates higher expected returns plan assets amortization million unrecognized loss expected increase pension expense following nine years approximately million per year several plans underfunded accrued benefit obligations exceeded accrued benefit liabilities december additional minimum liabilities established increase accrued benefit liabilities values underfunded accrued benefit obligations totaled million us unfunded benefit equalization plan plans uk japan canada belgium additional minimum liability offset creation million intangible asset million charge comprehensive income included stockholders ' equity recent decline global equity markets resulted decrease value assets company 's pension plans decline expected adversely affect company 's related accounting results future periods higher pension expense increased cash funding requirements company contributed defined benefit plans total million including contribution million fourth quarter company reduced assumed discount rate major pension plans response decline corporate bond yields company also reduced expected longterm rate return us plan assets following reassessment longterm outlook addition company revised based change expectations future terminations retirements retirement turnover assumptions pension expense company 's defined benefit pension plans expected increase approximately million compared reflecting among things lower assumed discount rate expected longterm rate return us plan assets negative asset returns principal defined contribution plan bristolmyers squibb savings investment program company 's contribution based employee contributions level company match company 's contributions plan million million million note postretirement benefit plans pensions company provides comprehensive medical group life benefits substantially us retirees elect participate comprehensive medical group life plans medical plan contributory contributions adjusted periodically vary date retirement original retiring company life insurance plan noncontributory plan assets consist principally equity securities fixedincome securities cost company 's postretirement benefit plans included following components dollars millions service costbenefits earned year interest cost accumulated postretirement benefit obligation expected earnings plan assets net amortization deferral curtailments net postretirement benefit expense weightedaverage actuarial assumptions company 's postretirement benefit plans follows december discount rate longterm rate return changes benefit obligation plan assets dollars millionsbenefit obligation beginning year service costbenefits earned year interest cost accumulated postretirement benefit obligation plan participants ' contributions actuarial gains losses curtailments benefits paid benefit obligation end year fair value plan assets beginning year actual earnings plan assets employer contribution plan participants ' contributions benefits paid fair value plan assets end year accumulated postretirement benefit obligation excess plan assets unrecognized prior service cost unrecognized net gains losses accrued postretirement benefit expense reported curtailments relate company 's restructuring divestiture activities measurement purposes annual rate increase per capita cost covered health care benefits participants assumed rate assumed decrease gradually remain level thereafter onepercentagepoint change assumed health care cost trend rates would following effects percentage percentage point increase point decrease dollars millions effect aggregate service interest cost components net postretirement benefit expense effect accumulated postretirement benefit obligation bristolmyers squibb company notes consolidated financial statements note litigation matters various lawsuits claims proceedings pending company certain subsidiaries accordance sfas accounting contingencies company records accruals contingencies probable liability incurred amount loss reasonably estimated years ended december company recognized million includes million discontinued operations million respectively related litigation matters significant company 's litigation matters described taxol litigation company filed several lawsuits asserting number generic drug companies infringed patents covering methods administering paclitaxel filed abbreviated new drug applications seeking regulatory approval sell paclitaxel actions consolidated discovery us district court district new jersey district court company assert monetary claim defendants sought prevent defendants marketing paclitaxel manner violates patents defendants asserted infringe company 's patents patents invalid unenforceable early district court invalidated claims company 's patents issue april us court appeals federal circuit affirmed district court 's summary judgment invalidity two claims patents issue two claims relate lowdose threehour administration paclitaxel patient given specified regimen premedicants administration paclitaxel appellate court remanded two claims district court proceedings company filed additional patent infringement suit another company seeking market generic paclitaxel september one defendants received final approval fda abbreviated new drug application paclitaxel marketing product fda since announced additional final approvals sales additional generic products begun defendants asserted counterclaims seeking damages alleged antitrust unfair competition violations company believed patents valid filed suits counterclaims asserted believed without merit lawsuits defendants asserted counterclaims settled defendants agreeing drop claims relating paclitaxel company granting licenses certain paclitaxel patent rights since filing initial patent infringement suits six private actions filed parties alleging antitrust consumer protection similar claims relating company 's actions obtain enforce patent rights plaintiffs seek declaratory judgment damages including treble andor punitive damages allowed disgorgement injunctive relief june group state attorneys general district colombia puerto rico virgin islands brought similar claims september federal trade commission ftc initiated investigation relating paclitaxelon january company announced reached agreements principle would settle substantially antitrust litigation surrounding taxol amount taxol antitrust settlements expected million full amount accrued third quarter certain important terms conditions settlements remain finalized certain settlements require court approval final approval state attorneys general taxol litigation contingent upon agreements relating terms injunctive relief among provisions remaining negotiated terms incorporating certain claimants including number health insurers existing settlement framework company discussions number insurers whether ultimately join proposed settlement predicted certainty time company also reached agreement ftc staff terms consent order would resolve ftc 's investigation proposed consent order subject review approval ftc commissioners respect abovementioned proposed settlements possible time reasonably assess final outcome lawsuits reasonably estimate possible loss range loss respect lawsuits proposed settlements become final resolve taxolrelated antitrust consumer protection similar claims company prevail final nonappealable determinations ensuing litigation impact could material buspar litigation november company obtained patent us patent ' patent relating method using buspar buspirone company timely submitted information relating ' patent fda listing fda publication commonly known orange book fda thereafter listed patent orange book delisting patent suits genericdrug manufacturers sued fda company compel delisting ' patent orange book although one district court declined order delisting ' patent another ordered company cause delisting patent orange book company complied court 's order appealed decision united states court appeals federal circuit appellate court reversed district court ordered delisting concurrently company sought enforce ' patent actions two generic drug manufacturers antitrust suits following delisting ' patent orange book number purchasers buspirone several generic drug makers filed lawsuits company alleging improperly triggered statutory marketing exclusivity plaintiffs claimed violation antitrust consumer protection similar laws attorneys general states puerto rico also filed suit company parallel allegations plaintiffs amended allegations include charges agreement company generic company improperly blocked entry generic buspirone market plaintiffs seek declaratory judgment damages including treble andor punitive damages allowed disgorgement injunctive relief multidistrict litigation mdl proceedings judicial panel mdl granted company 's motions patent antitrust cases consolidated single forum court buspirone litigations pending issued two opinions dated february first opinion court found ' patent cover uses buspirone therefore infringed second opinion court denied company 's motion dismiss federal antitrust various state law claims second opinion allows claims company proceed except federal antitrust claims damages accrued four years filing complaints government investigations ftc number state attorneys general initiated investigations concerning matters alleged antitrust suits discussed company cooperated investigations number attorneys general filed action company noted proposed settlements january company announced reached agreements principle would settle substantially antitrust litigation surrounding buspar amount buspar settlements expected million million accrued fourth quarter million accrued first quarter million accrued third quarter written settlement agreements number parties signed certain settlements require court approval number health insurers agreed proposed settlement framework whether cases ultimately settled predicted certainty time company also reached agreement ftc staff terms consent order would resolve ftc 's investigation proposed consent order subject review approval ftc commissioners respect abovementioned proposed settlements buspar antitrust litigation possible time reasonably assess final outcome lawsuits reasonably estimate possible loss range loss respect lawsuits proposed settlements become final resolve busparrelated antitrust consumer protection similar claims company prevail final nonappealable determinations ensuing litigation impact could material vanlev litigation april may june company former chairman board chief executive officer charles heimbold jr former chief scientific officer peter ringrose phd named defendants number class action lawsuits alleging violations federal securities laws regulations actions consolidated one action us district court district new jersey plaintiff claims defendants disseminated materially false misleading statements andor failed disclose material information concerning safety efficacy commercial viability product vanlev period november april may plaintiff submitted amended complaint adding allegations company present chairman board chief executive officer peter r dolan former chairman board chief executive officer charles heimbold jr former chief scientific officer peter ringrose phd disseminated materially false misleading statements andor failed disclose material information concerning safety efficacy commercial viability ofvanlev period april march number related class actions making essentially allegations also filed us district court southern district new york actions transferred us district court district new jersey plaintiff purports seek compensatory damages costs expenses behalf shareholders possible time reasonably assess final outcome litigation reasonably estimate possible loss range loss respect litigation company prevail final nonappealable determinations litigation impact could material plavix litigation company part entity plaintiff two pending patent infringement lawsuits united states district court southern district new york entitled sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceuticals holding partnership v apotex inc apotex corp cv rws sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceuticals holding partnership v dr reddy 's laboratories ltd dr reddy 's laboratories inc cv rws suits based us patent discloses claims among things hydrogen sulfate salt clopidogrel marketed plavix us patent discloses claims among things use clopidogrel prevent secondary ischemic event plaintiffs ' infringement position based defendants ' filing abbreviated new drug applications fda seeking approval sell generic clopidogrel prior expiration patents suit possible time reasonably assess final outcome lawsuits reasonably estimate possible loss range loss respect lawsuits patent protection plavix lost impact company 's operations could material securities matters period march may company number current former officers named defendants number securities class action lawsuits alleging violations federal securities laws regulations plaintiffs variously alleged defendants disseminated materially false misleading statements failed disclose material information concerning three different matters safety efficacy commercial viability vanlev discussed company 's sales incentives certain wholesalers inventory levels wholesalers company 's investment relations imclone imclone 's product erbitux discussed allegations concerning vanlev transferred us district court district new jersey consolidated action pending remaining actions consolidated pending us district court southern district new york allegations remaining actions cover period january april plaintiffs seek compensatory damages costs expenses october number company 's officers directors former directors named defendants shareholder derivative suit pending us district court southern district new york company nominal defendant suit alleges among things violations federal securities laws breaches contract fiduciary duty connection company 's sales incentives certain wholesalers inventory levels wholesalers investment imclone imclone 's product erbitux two similar actions pending new york state court plaintiffs seek damages costs attorneys ' fees april sec initiated inquiry wholesaler inventory issues referenced became formal investigation august december investigation expanded include certain accounting issues including issues related establishment reserves accounting certain asset sales october united states attorney 's office district new jersey announced investigation wholesaler inventory issues referenced since expanded cover subject matter sec investigation company cooperating investigations company 's investigation also continuing possible time reasonably assess final outcome litigations investigations reasonably estimate possible loss range loss respect litigations investigations company producing documents actively cooperating investigations investigations could result assertion criminal andor civil claims company prevail final nonappealable determinations litigations investigations impact could material erisa litigation december first quarter company others named defendants number class actions brought federal employee retirement income security act erisa cases pending us district courts southern district new york district new jersey plaintiffs allege defendants breached various fiduciary duties imposed erisa owed participants bristolmyers squibb company savings investment program program including duty disseminate material information concerning safety data company 's product vanlev company 's sales incentives certain wholesalers inventory levels wholesalers company 's investment relations imclone imclone 's product erbitux connection allegations plaintiffs assert defendants breached fiduciary duties diversify program assets monitor investment alternatives avoid conflicts interest remedy alleged fiduciary breaches cofiduciaries case pending district new jersey plaintiffs additionally allege violation defendants duty disseminate material information concerning alleged anticompetitive activities related company 's products buspar taxol pravachol plaintiffs seek recover losses caused defendants ' alleged violations erisa attorneys ' fees possible time reasonably assess final outcome matters reasonably estimate possible loss range loss respect lawsuits company prevail final nonappealable determinations matters impact could material average wholesale pricing litigation company together number pharmaceutical manufacturers defendant series state federal actions private plaintiffs brought purported class actions complaints filed attorneys general two states one county alleging manufacturers ' reporting prices certain products resulted false overstated average wholesale price awp turn improperly inflated reimbursement paid medicare beneficiaries insurers state medicaid programs medical plans others health care providers prescribed administered products federal cases many state cases including attorney general cases removed federal courts consolidated pretrial purposes transferred united states district court district massachusetts pharmaceutical industry average wholesale price litigation awp multidistrict litigation september several private plaintiffs awp multidistrict litigation filed master consolidated complaint master complaint superseded complaints pre consolidated constituent cases master complaint asserts claims federal rico statute state consumer protection fair trade statutes company defendants moved dismiss master complaint motions heard january nevada montana attorneys general moved respective cases remanded state court argument motion held march company also defendant related state court proceedings new york new jersey california arizona tennessee one federal court proceeding new york commenced county suffolk new york new jersey state court proceedings currently stayed company defendants removed intend remove state court cases federal court seek transferred awp multidistrict litigation company anticipates county suffolk case also transferred plaintiffs seek damages well injunctive relief aimed manufacturer price reporting practices cases preliminary stage company unable assess outcome possible effect business profitability reasonably estimate possible loss range loss respect cases company together number pharmaceutical manufacturers also received subpoenas document requests various government agencies seeking records relating pricing marketing practices drugs covered medicare andor medicaid requests records come united states attorney 's office district massachusetts office inspector general department health human services conjunction civil division department justice several states company producing documents actively cooperating investigations could result assertion criminal andor civil claims company unable assess outcome reasonably estimate possible loss range loss respect investigations could include imposition fines penalties administrative remedies breast implant litigation company together subsidiary medical engineering corporation mec certain companies remains defendant number claims lawsuits alleging damages personal injuries various types resulting polyurethanecovered breast implants smoothwalled breast implants formerly manufactured mec related company vast majority claims company direct lawsuits resolved settlements trial likewise claims potential claims company registered nationwide class action settlement approved federal district court birmingham alabama revised settlement resolved revised settlement company established accruals respect breast implant product liability litigation company believes possible loss addition amounts accrued material note selected quarterly financial data unaudited first second third fourth dollars millions except per share data quarter quarter quarter quarter year net sales gross margin earnings continuing operations discontinued operations net net earnings earnings per common share basic earnings continuing operations discontinued operations net net earnings diluted earnings continuing operations discontinued operations net net earnings dividends declared per common share first second third fourth dollars million except per share data quarter quarter quarter quarter year net sales gross margin earnings loss continuing operations discontinued operations net net earnings earnings per common share basic earnings continuing operations discontinued operations net net earnings diluted earnings continuing operations discontinued operations net net earnings dividends declared per common share note earnings per share quarters may add amounts year period computed discrete basis includes gain sale product lines million first quarter first third fourth quarters include writeoffs acquired process research development million million million respectively second fourth quarters include provisions restructuring items million million respectively first third quarters include reversals prior period restructuring items million million respectively litigation settlement charges million million included first third quarters respectively also third quarter includes million asset impairment charge imclone first second third fourth quarters include gain sales businessesproduct lines million million million million respectively first third fourth quarters include writeoffs acquired inprocess research development million million million respectively second quarter includes reversal prior period restructuring liabilities million third fourth quarters include provisions restructuring items million million respectively third fourth quarters include litigation settlement charges million million respectively first quarter discontinued operations results included purchase price adjustment related clairol transaction million third quarter discontinued operations results included litigation provision million gain adjustment relating clairol transaction million fourth quarter discontinued operations results included gain sale business related clairol transaction billion common equivalent shares excluded computation diluted earnings per share effect would antidilutive follows millions first second third fourth quarter quarter quarter quarter year report independent accountants board directors stockholders bristolmyers squibb company opinion consolidated financial statements listed index appearing item present fairly material respects financial position bristolmyers squibb company subsidiaries december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america addition opinion financial statement schedule listed index appearing item presents fairly material respects information set forth therein read conjunction related consolidated financial statements financial statements financial statement schedule responsibility company 's management responsibility express opinion financial statements financial statement schedule based audits conducted audits statements accordance auditing standards generally accepted united states america require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements assessing accounting principles used significant estimates made management evaluating overall financial statement presentation believe audits provide reasonable basis opinion described note accounting policies company changed method accounting business combinations goodwill arising transactions consummated subsequent june changed method accounting goodwill arising transactions consummated prior july impairment longlived assets pricewaterhousecoopers llp pricewaterhousecoopers llp new york new york march item changes disagreements accountants accounting financial disclosurenone part iii item directors executive officers registrant reference made proxy statement filed april respect directors registrant incorporated herein reference made part hereof response information required item b information required item respect executive officers registrant included part ia reliance general instruction g instruction item b regulation sk item executive compensation reference made proxy statement filed april respect executive compensation incorporated herein reference made part hereof response information required item item security ownership certain beneficial owners management reference made proxy statement filed april respect security ownership certain beneficial owners management incorporated herein reference made part hereof response information required item item certain relationships related transactions reference made proxy statement filed april respect certain relationships related transactions incorporated herein reference made part hereof response information required item item controls procedures company restated consolidated financial statements three years ended december including corresponding interim periods quarterly periods ended march june description restatement see amendment company 's annual report year ended december amendments company 's quarterly reports form qa quarterly periods ended march june within days prior filing date company carried evaluation supervision participation chief executive officer chief financial officer pursuant rule promulgated securities exchange act amended effectiveness design operation disclosure controls procedures making evaluation company considered matters relating restatement previously issued financial statements including substantial process undertaken ensure material adjustments necessary correct previously issued financial statements recorded company believes certain restatement adjustments occurred company 's control processes procedures related matters underlying adjustments effective company also considered two material weaknesses defined standards established american institute certified public accountants relating accounting public financial reporting significant matters initial recording management review oversight certain accounting matters identified communicated company audit committee company 's independent auditors connection audits restatement previously issued financial statements consolidated financial statements year ended december last year company searched hired new chief financial officer outside company restaffed controller position created position chief compliance officer changed leadership pharmaceuticals group response wholesaler inventory buildup matters identified restatement adjustments direction audit committee last year senior management directed company dedicate resources take steps strengthen control processes procedures order identify rectify past accounting errors prevent recurrence circumstances resulted need restate prior period financial statements company also revised budgeting process emphasize bottomup approach contrast topdown approach company implemented review certification process annual quarterly reports securities exchange act amended exchange act well processes designed enhance monitoring wholesaler inventories addition company process expanding business risks disclosure group includes senior management including chief executive officer chief financial officer taking number additional steps designed create open environment communications flow information throughout company company continues identify implement actions improve effectiveness disclosure controls procedures internal controls including plans enhance resources training respect financial reporting disclosure responsibilities review actions audit committee independent auditors based evaluation company 's chief executive officer chief financial officer concluded evaluation date disclosure controls procedures reasonably designed ensure information required disclosed company reports files submits exchange act recorded processed summarized reported within time periods specified rules forms securities exchange commission described since evaluation date company 's management internal controls significant changes internal controls factors could significantly affect internal controls part iv item exhibits financial statement schedules reports form k number consolidated financial statements notes consolidated financial statements report independent accountants financial statement schedule schedule number number valuation qualifying accounts ii schedules included additional financial data omitted applicable required information included financial statements notes thereto exhibit list exhibits listed identified numbers corresponding exhibit table item regulation sk exhibits designated two asterisks management contracts compensatory plans arrangements required filed pursuant item unless otherwise indicated exhibits part commission file number restated certificate incorporation bristolmyers squibb company incorporated herein reference exhibit registrant 's registration statement form registration statement dated march amended may certificate amendment incorporated herein reference exhibit fiscal year ended december b bylaws bristolmyers squibb company amended march filed herewith letter agreement dated march incorporated herein reference exhibit fiscal year ended december b indenture dated june bristolmyers squibb company chase manhattan bank national association trustee incorporated herein reference exhibit form k dated may filed june c form debenture due bristolmyers squibb company incorporated herein reference exhibit form k dated may filed june form debenture due bristolmyers squibb company incorporated herein reference exhibit e fiscal year ended december e form debenture due bristolmyers squibb company incorporated herein reference exhibit f form q quarterly period ended september f five year competitive advance revolving credit facility agreement dated march among bristolmyers squibb company borrowing subsidiaries defined agreement lenders listed schedule agreement chase manhattan bank administrative agent citibank na administrative agent incorporated herein reference exhibit f fiscal year ended december g day competitive advance revolving credit facility agreement dated march among bristolmyers squibb company borrowing subsidiaries defined agreement lenders listed schedule agreement chase manhattan bank administrative agent citibank na administrative agent incorporated herein reference exhibit g fiscal year ended december h form note due form note due bristolmyers squibb company incorporated herein reference form b filed september bristolmyers squibb company stock incentive plan effective may amended effective july incorporated herein reference exhibit form q quarterly period ended june b bristolmyers squibb company stock incentive plan effective may amended effective july incorporated herein reference exhibit b form q quarterly period ended june c bristolmyers squibb company teamshare stock option plan amended restated effective september filed herewith bristolmyers squibb company executive performance incentive plan incorporated herein reference exhibit b fiscal year ended december e bristolmyers squibb company stock option plan amended restated january amended november incorporated herein reference exhibit c fiscal year ended december f squibb corporation option restricted stock performance unit plan amended incorporated herein reference exhibit b fiscal year ended december g squibb corporation option restricted stock performance unit plan amended adopted incorporated herein reference exhibit k squibb corporation fiscal year ended december file amended effective july incorporated herein reference exhibit c fiscal year ended december h bristolmyers squibb company performance incentive plan amended adopted incorporated herein reference exhibit fiscal year ended december amended january incorporated herein reference exhibit b fiscal year ended december amended april incorporated herein reference exhibit b fiscal year ended december amended effective january incorporated herein reference exhibit fiscal year ended december amended effective january incorporated herein reference exhibit fiscal year ended december benefit equalization plan bristolmyers squibb company subsidiary affiliated corporations participating bristolmyers squibb company retirement income plan bristolmyers squibb puerto rico inc retirement income plan amended amended restated january amended effective october incorporated herein reference exhibit e fiscal year ended december amended effective february incorporated herein reference exhibit e fiscal year ended december j benefit equalization plan bristolmyers squibb company subsidiary affiliated corporations participating bristolmyers squibb company savings investment program amended restated effective january incorporated herein reference exhibit h fiscal year ended december k squibb corporation supplementary pension plan amended previously amended restated incorporated herein reference exhibit g fiscal year ended december amended september incorporated herein ence exhibit g fiscal year ended december bristolmyers squibb company restricted stock award plan amended adopted november incorporated herein reference bit fiscal year ended december amended december incorporated herein e exhibit fiscal year ended december amended effective july incorporated reference exhibit h fiscal year ended december amended effective december ated herein reference exhibit h fiscal year ended december bristolmyers squibb company retirement income plan nonemployee directors amended march incorporated herein e exhibit k fiscal year ended december n bristolmyers squibb company deferred compensation plan nonemployee directors amended january incorporated reference exhibit fiscal year ended december bristolmyers squibb company nonemployee directors ' stock option plan amended approved stockholders may ated herein reference exhibit registration statement form amended may incorporated reference exhibit c fiscal year ended december amended january rated herein reference exhibit fiscal year ended december p squibb corporation deferral plan fees outside directors amended adopted incorporated herein reference exhibit e squibb corporation fiscal year ended december file amended effective december corporated herein reference exhibit fiscal year ended december q amendment company 's plans agreements legal documents writings pursuant action board directors october reflect change company 's name bristolmyers squibb company incorporated herein reference exhibit v fiscal year ended december r employment separation agreement dated june registrant peter ringrose incorporated herein reference exhibit r form q quarterly period ended june form agreement entered registrant following officers effective following dates lamberto august harrison bains jr may stephen e bear december andrew r j bonfield september wendy dixon march peter r dolan july donald j hayden jr july tamar howson october john l mcgoldrick august dean j mitchell may peter ringrose phd august john l august incorporated herein reference exhibit q form q quarterly period ended september subsidiaries registrant filed herewith consent pricewaterhousecoopers llp filed herewith section certification letter filed herewith section certification letter filed herewithb reports form k november company filed form k connection expected restatement including exhibit form k press release dated october november company filed form k announcing expected filing dates third quarter form q amended filings disclosing certain matters connection restatement delay filing third quarter form q company included exhibit form k press release dated november indicates brand names products registered trademarks owned company subsidiaries erbitux trademark imclone systems incorporated avapro aprovel avalide plavix trademarks sanofisynthelabo sa glucophage ir glucophage xr glucovance metaglip trademarks merck sante sas associate merck kgaa darmstadt germany abilify trademark otsuka pharmaceutical company ltd corzide delestrogen corgard florinef trademarks king pharmaceuticals inc viactiv trademark mcneilppc inc solage trademark galderma sa ovcon trademark warner chilcott inc sea breeze trademark shiseido company ltd vaniqa trademark women first healthcare inc moisturel duricef estrace trademarks galen chemicals limited signatures pursuant requirements section securities exchange act registrant duly caused report signed behalf undersigned thereunto duly authorized bristolmyers squibb company registrant peter r dolan peter r dolan chairman board directors chief executive officer date march pursuant requirements securities exchange act report signed following persons behalf registrant capacities dates indicated signature title date peter r dolan march chairman board directors chief executive peter r dolan officer principal executive officer andrew rj bonfield march senior vice president chief financial officer principal andrew rj bonfield financial officer david l zabor march vice president controller principal accounting david l zabor officer robert e allen march robert e allen director lewis b campbell march lewis b campbell director vance coffman march vance coffman director ellen v futter march ellen v futter directors louis v gerstner jr march louis v gerstner jr director laurie h glimcher md march laurie h glimcher md director leif johansson march leif johansson director james robinson iii march james robinson iii director louis w sullivan md march louis w sullivan md director certifications pursuant section sarbanesoxley act certification chairman board chief executive officer peter r dolan certify reviewed annual report bristolmyers squibb company based knowledge annual report contain untrue statement material fact omit state material fact necessary make statements made light circumstances statements made misleading respect period covered annual report based knowledge financial statements financial information included annual report fairly present material respects financial condition results operations cash flows registrant periods presented annual report registrant 's certifying officers responsible establishing maintaining disclosure controls procedures defined exchange act rules registrant company designed disclosure controls procedures ensure material information relating registrant including consolidated subsidiaries made known us others within entities particularly period annual report prepared b evaluated effectiveness registrant 's disclosure controls procedures date within days prior filing date annual report evaluation date c presented annual report company 's conclusions effectiveness disclosure controls procedures based evaluation evaluation date registrant 's certifying officers disclosed based company 's recent evaluation registrant 's auditors audit committee registrant 's board directors persons performing equivalent function significant deficiencies design operation internal controls could adversely affect registrant 's ability record process summarize report financial data identified registrant 's auditors material weaknesses internal controls b fraud whether material involves management employees significant role registrant 's internal controls registrant 's certifying officers indicated annual report whether significant changes internal controls factors could significantly affect internal controls subsequent date company 's recent evaluation including corrective actions regard significant deficiencies material weaknesses date march peter r dolan peter r dolan chairman board chief executive officer certification senior vice president chief financial officer andrew rj bonfield certify reviewed annual report bristolmyers squibb company based knowledge annual report contain untrue statement material fact omit state material fact necessary make statements made light circumstances statements made misleading respect period covered annual report based knowledge financial statements financial information included annual report fairly present material respects financial condition results operations cash flows registrant periods presented annual report registrant 's certifying officers responsible establishing maintaining disclosure controls procedures defined exchange act rules registrant company designed disclosure controls procedures ensure material information relating registrant including consolidated subsidiaries made known us others within entities particularly period annual report prepared b evaluated effectiveness registrant 's disclosure controls procedures date within days prior filing date annual report evaluation date c presented annual report company 's conclusions effectiveness disclosure controls procedures based evaluation evaluation date registrant 's certifying officers disclosed based company 's recent evaluation registrant 's auditors audit committee registrant 's board directors persons performing equivalent function significant deficiencies design operation internal controls could adversely affect registrant 's ability record process summarize report financial data identified registrant 's auditors material weaknesses internal controls b fraud whether material involves management employees significant role registrant 's internal controls registrant 's certifying officers indicated annual report whether significant changes internal controls factors could significantly affect internal controls subsequent date company 's recent evaluation including corrective actions regard significant deficiencies material weaknesses date march andrew rj bonfield andrew rj bonfield senior vice president chief financial officer exhibit index